

Montréal

6TH World Congress of
Cutaneous Lymphomas

JUNE 25 - 27, 2026

2026 Congress Program



www.6WCCL.org

**6TH WORLD CONGRESS OF CUTANEOUS LYMPHOMAS
IS HONORED TO WELCOME**



TABLE OF CONTENTS

WELCOME TO MONTRÉAL	2
WELCOME FROM 6WCCL CO-CHAIRS	3
CONGRESS COMMITTEE	4
ASSOCIATION CONTACTS	6
GENERAL CONGRESS INFORMATION	8
CONGRESS MEALS / WIFI	9
SOCIAL GATHERINGS	10
ACCREDITATION AND CONGRESS LEARNING OBJECTIVES	11
SPONSOR ACKNOWLEDGEMENT	12
ISCL 2026 LIFETIME ACHIEVEMENT AWARDEES	13
PLENARY AND SYMPOSIA INFORMATION	14
PROGRAM AT A GLANCE	16
DETAILED PROGRAM	18
POSTERS	37
AUTHOR INDEX	42



WELCOME TO MONTRÉAL

6th World Congress of Cutaneous Lymphomas

June 25-27, 2026

Le Westin Montréal | Montréal, QC, Canada

This activity is brought to you by
ISCL (International Society for Cutaneous Lymphomas)

International Society for
Cutaneous Lymphomas



CONGRESS HIGHLIGHTS INCLUDE:

- Lectures and scientific abstracts on pathology, genetics, tumor microenvironment, therapeutics, clinical studies, quality of life and leading-edge research in cutaneous lymphomas
- Debates and discussions on key controversies
- Interactive question and answer sessions
- Poster sessions and guided poster walk with our experts
- Networking opportunities among clinicians, investigators and scientists across institutions and geographical borders

WELCOME FROM 6WCCL CO-CHAIRS

Dear Colleagues,

On behalf of the International Society for Cutaneous Lymphomas and the 6WCCL Organizing Committee, it is our great pleasure to welcome you to the 6th World Congress of Cutaneous Lymphomas (6WCCL) in Montréal, Québec, Canada.

We are truly excited to share this year's educational program with you. It brings together a diverse, international faculty and offers a rich blend of cutting-edge science, clinical insights, and interactive discussions. From the latest research advances to practical approaches in patient care, we hope the program will inspire meaningful dialogue and new collaborations across our global community.

We are equally delighted to host you in Montréal—a vibrant, welcoming city known for its unique blend of cultures, history, and cuisine. We encourage you to take time to experience its charm while connecting with colleagues from around the world.

We hope your time at 6WCCL will be both memorable and engaging, and we thank you for being part of this important gathering.



Prof. Julia Scarisbrick, MBChB, MD
ISCL President
Co-Chair, 6WCCL




Dr. Ivan V. Litvinov, MD, PhD, FRCPC
ISCL Treasurer
Co-Chair, 6WCCL

JOIN THE ISCL!



We encourage you to join the International Society for Cutaneous Lymphomas, the organizing society of the World Congress of Cutaneous Lymphomas. The ISCL is dedicated to the treatment, research and caring of patients with cutaneous lymphomas. The ISCL was founded in 1992 at the World Congress of Dermatology in New York and among its aims are to increase knowledge of lymphoproliferative and related disorders of the skin, foster collaboration among clinicians and scientists, and promote dissemination of scientific information.

To apply for membership, visit <https://cutaneouslymphoma.org/about-membership/> or scan this QR code.



CONGRESS COMMITTEE

WORLD CONGRESS ORGANIZING COMMITTEE

CO-CHAIR: Julia Scarisbrick, MBChB, MD |
United Kingdom,
CO-CHAIR: Ivan Litvinov, MD, PhD | Canada

Jade Cury Martins, MD, PhD | Brazil
Paula Enz, MD | Argentina
Larisa J. Geskin, MD | USA
Robert Gniadecki, MD, PhD | Canada
Emmilia Hodak, MD | Israel
Steven M. Horwitz, MD | USA
Thomas Kupper, MD | USA
Tomomitsu Miyagaki, MD, PhD | Japan
Pablo Ortiz-Romero, MD, PhD | Spain
Kevin L. Pehr, MD | Canada
Gizelle Popradi, MDCM | Canada
Christiane Querfeld, MD, PhD | USA
Rudolf Stadler, MD, PhD | Germany
Yang Wang, MD | China

FUNDRAISING COMMITTEE

CHAIR: Ivan Litvinov, MD, PhD | Canada

Oleg E. Akilov, MD, PhD | USA
Martine Bagot, MD, PhD | France
Larisa J. Geskin, MD | USA
Youn H. Kim, MD | USA
Christopher McCormack, MBBS | Australia
José Antonio Sanches, Jr., MD, PhD | Brazil
Rudolf Stadler, MD, PhD | Germany

6WCL PROMOTIONS COMMITTEE

Miranda Branyiczky | Canada
Armin Farzad | Canada
Megan Lowe | Canada
Ajay Pandey | Canada
Sophie Serfaty | Canada

SCIENTIFIC PROGRAM CO-CHAIRS

CO-CHAIR: Julia Scarisbrick, MBChB, MD |
United Kingdom
CO-CHAIR: Steven M. Horwitz, MD | USA

SCIENTIFIC PROGRAM COMMITTEE, SESSION PRIMARY CHAIRS AND CO-CHAIRS

Oleg E. Akilov, MD, PhD | USA
Pamela Allen, MD, MSc | USA
Chalid Assaf, MD, PhD | Germany
Martine Bagot, MD, PhD | France
Maxime Battistella, MD, PhD | France
Marie Beylot-Barry, MD, PhD | France
Patrick Brunner, MD, MSc | USA
Antonio Cozzio, MD, PhD | Switzerland
Jade Cury Martins, MD, PhD | Brazil
Julia Dai, MD | USA
Adele de Masson, MD | France
Paula Enz, MD | Argentina
Francine Foss, MD | USA
Shamir Geller, MD | USA
Larisa J. Geskin, MD | USA
Robert Gniadecki, MD, PhD | Canada
Amrita Goyal-O'Leary, MD | USA
Alejandro Gru, MD | USA
Emmanuella Guenova, MD, PhD | Austria
Joan Guitart, MD | USA
Emmilia Hodak, MD | Israel
Auris Huen, MD, PharmD | USA
Kevin Imrie, MD | Canada
Swaminathan P. (Swami) Iyer, MD | USA
Constanze Jonak, MD | Austria
Michael Khodadoust, MD, PhD | USA
Youn H. Kim, MD | USA
Ellen Kim, MD | USA
Philippe Lefrancois, MD, PhD | Canada
Ivan Litvinov, MD, PhD | Canada
Tomomitsu Miyagaki, MD, PhD | Japan

Denis Miyashiro, MD, PhD | Brazil
Montserrat Molgo, MD | Chile
Alison Moskowitz, MD | USA
Neda Nikbakht, MD, PhD | USA
Elise Olsen, MD | USA
Pablo Ortiz-Romero, MD, PhD | Spain
Evangelia Papadavid, MD, PhD | Greece
Kevin L. Pehr, MD | Canada
Gizelle Popradi, MDCM | Canada
H. Miles Prince, MBBS, MD | Australia
Barbara Pro, MD | USA
Melissa Pulitzer, MD | USA

Pietro Quaglino, MD | Italy
Christiane Querfeld, MD, PhD | USA
David Roberge, MD | Canada
Alain Rook, MD | USA
Sima Rozati, MD, PhD | USA
José Antonio Sanches, Jr., MD, PhD | Brazil
Rudolf Stadler, MD, PhD | Germany
Maarten H. Vermeer, MD, PhD | Netherlands
Yang Wang, MD | China
Rein Willemze, MD | Netherlands
Jasmine Zain, MD | USA

FACULTY DISCLOSURES OF CONFLICT

All disclosed conflicts of interest among the scientific planning committee were reviewed and appropriately managed in accordance with accreditation requirements to uphold educational integrity. Committee member disclosures can be found on the USB Memory stick handed out at registration.



ASSOCIATION CONTACTS



INTERNATIONAL SOCIETY FOR CUTANEOUS LYMPHOMAS (ISCL)

ISCL HEADQUARTERS

675 Tollgate Rd., Suite G,
Elgin, IL 60123 USA
Phone: +1-312-585-8941
www.cutaneouslymphoma.org

EXECUTIVE DIRECTOR: Victoria Ceh, MPA
info@cutaneouslymphoma.org

ISCL BOARD OF DIRECTORS

PRESIDENT: Julia Scarisbrick, MBChB, FRCP,
MD | United Kingdom

SECRETARY: Steven M. Horwitz, MD | USA

TREASURER: Ivan Litvinov, MD, PhD, FRCPC
| Canada

IMM PAST-PRESIDENT: Emmilia Hodak, MD
| Israel

Oleg E. Akilov, MD, PhD | USA

Antonio Cozzio, MD, PhD | Switzerland

Jade Cury Martins, MD, PhD | Brazil

Paula A. Enz, MD | Argentina

Alejandro A. Gru, MD | USA

Emmanuella Guenova, MD, PhD | Austria

Michael Khodadoust, MD, PhD | USA

Youn H. Kim, MD | USA

Tomomitsu Miyagaki, MD, PhD | Japan

Denis Miyashiro, MD, PhD | Brazil

Montserrat Molgo, MD | Chile

Pablo L. Ortiz-Romero, MD, PhD | Spain

Evangelia Papadavid, MD | Greece

Barbara Pro, MD | USA

Christiane Querfeld, MD, PhD | USA

Rudolf Stadler, MD | Germany

Yang Wang, MD, PhD | China



The future of cancer therapy

**EUROPEAN ORGANISATION FOR
RESEARCH AND TREATMENT OF CANCER
(EORTC) CUTANEOUS LYMPHOMA
TUMOUR GROUP (CLTG)**

EORTC HEADQUARTERS

Avenue Emmanuel Mounier 83/11
1200 Brussels, Belgium
[https://www.eortc.org/research_field/
cutaneous-lymphoma/](https://www.eortc.org/research_field/cutaneous-lymphoma/)

CLTG OFFICERS

CHAIR: Evangelia Papadavid, MD, PhD |
Greece

SECRETARY: Emmanuella Guenova, MD, PhD
| Austria

TREASURER: Maxime Battistella, MD, PhD |
France

IMM-PAST CHAIR: Julia Scarisbrick, MBChB,
MD | United Kingdom

<https://eortc-cltg.org>

**2026 Annual Meeting: October 8 - 10,
2026, Berlin**



**UNITED STATES CUTANEOUS LYMPHOMA
CONSORTIUM (USCLC)**

USCLC HEADQUARTERS

400 Winding Creek Blvd.
Mechanicsburg, PA 17050, USA
Phone: 866-270-5332
www.usclc.org

ASSOCIATION EXECUTIVE: Sharon Kim
usclc-exec@pamedsoc.org

BOARD OF DIRECTORS

PRESIDENT: Alejandro A. Gru, MD

SECRETARY-TREASURER: Larisa J. Geskin,
MD

IMM-PAST PRESIDENT: Francine M. Foss, MD

Stefan K. Barta, MD
Kimberly Bohjanen, MD
Auris Huen, MD
Youn H. Kim, MD
Mary Jo Lechowicz, MD
Aaron Mangold, MD
Sima Rozati, MD, PhD
Peggy Wu, MD
Jasmine Zain, MD

REGISTRY CO-CHAIRS: Elise A. Olsen, MD,
and Joi Carter, MD

GENERAL CONGRESS INFORMATION

CONGRESS NAME BADGE

Official congress name badge must be worn at all times to gain and maintain access to all 6WCCL activities. Please Note: Some activities require preregistration/prepaid tickets (6WCCL Gala Dinner) or are by invitation only.

REGISTRATION DESK

Le Westin Montréal Hotel, 270 rue Saint-Antoine West, Montréal
11th Floor, Montréal Ballroom Foyer

Hours

Wednesday, June 24 | 15:00 - 18:00
Thursday, June 25 | 06:30 - 17:30
Friday, June 26 | 06:30 - 17:30
Saturday, June 27 | 07:00 - 15:00

EDUCATIONAL SESSIONS

General Session: *Montréal Ballroom, 11th Floor*

Breakout Sessions: *Fortifications Ballroom, 9th Floor*

SPEAKER CENTRE

The Speaker Centre is located in *Ville Marie B, 9th Floor*. PowerPoint presentations should be brought to the Speaker Centre no later than four (4) hours prior to the session time*.

Hours

Wednesday, June 24 | 12:00 - 18:00
Thursday, June 25 | 06:30 - 17:30
Friday, June 26 | 06:30 - 17:30
Saturday, June 27 | 07:00 - 13:00

CONGRESS MEALS AND BREAKS

Accredited Symposia:

A hot plated lunch will be served during the Accredited Symposia on Thursday, June 25 and Friday, June 26. Seating is based on first available and is open to Health Care Professionals (HCP), on a priority basis. Thank you to our sponsors for understanding.

For sponsors and attendees not attending the Accredited Symposia a lunch buffet will be offered in the Exhibit Hall area.

Breakfast, breaks, and lunch will be provided in the **Exhibit Hall, Grande Place, 8th Floor** during the following times:

THURSDAY, JUNE 25	FRIDAY, JUNE 26	SATURDAY, JUNE 27
07:00-20:00 Exhibits open	07:00 - 18:30 Exhibits open	07:15 - 11:00 Exhibits open
07:00 - 08:00 Breakfast	07:00 - 08:00 Breakfast	07:15 - 08:15 Breakfast
10:00 - 10:40 Coffee break	10:15 - 10:55 Coffee break	10:15 - 10:55 Coffee break
12:00 - 13:15 Lunch buffet	12:30 - 13:55 Lunch buffet	12:55 - 13:55 Lunch buffet <i>served in the Montréal Foyer</i>
17:30 - 18:30 Poster Session , Chaired by Dr. Paula Enz Even numbered authors standby	17:30 - 18:30 Poster Session Chaired by Dr. Pablo Ortiz- Romero Odd numbered authors standby	
18:00 - 20:00 Welcome Reception	19:00 - 22:30 Congress Dinner <i>Montréal Ballroom, paid ticket required</i>	

WIFI

Network: Westin_Conference

PW: Westin2026

NOTE: **pw is case-sensitive**



SOCIAL GATHERINGS

We look forward to attendees participating in the 6th World Congress of Cutaneous Lymphomas' social gatherings, where participants will be able to network with colleagues and create new connections and opportunities for collaboration.

Look for the 6WCCL backdrop and ISCL letters for photo opportunities to share on your social media.

CONGRESS WELCOME RECEPTION

Thursday, June 25, 2026 | 18:00 - 20:00

Exhibit Hall, Grande Place, 8th Floor

Complimentary for 6WCCL registered conference participants

CONGRESS DINNER

Friday, June 26, 2026 | 19:00 - 22:30

Montréal Ballroom

Cocktail Attire

Paid Ticket Required. Limited availability. Please check at the registration desk if you have not purchased a ticket.



ACCREDITATION AND CONGRESS LEARNING OBJECTIVES

At the conclusion of this congress, participants will be able to:

- **Apply current diagnostic criteria and clinicopathologic** correlations to accurately distinguish among major subtypes of cutaneous lymphomas, including mycosis fungoides, Sézary syndrome, and rarer primary cutaneous lymphoproliferative disorders.
- **Integrate histopathologic, immunophenotypic, and molecular findings** into staging and risk stratification of patients with cutaneous lymphomas to support evidence-based clinical decision-making.
- **Select appropriate skin-directed and systemic treatment strategies** for patients with cutaneous lymphoma based on disease subtype, stage, symptom burden, and prior treatment response.
- **Evaluate emerging and novel therapies** (including targeted agents, immunotherapies, and combination approaches) and determine how recent clinical trial data can be incorporated into real-world practice.
- **Differentiate management approaches for early-stage versus advanced-stage disease**, including indications for escalation of therapy and referral for specialized or multidisciplinary care.
- **Recognize and manage treatment-related toxicities and quality-of-life issues**, including pruritus, infections, and long-term therapy complications, to optimize patient outcomes.
- **Apply standardized response assessment tools and follow-up strategies** to monitor disease progression, treatment effectiveness, and relapse in patients with cutaneous lymphoma.
- **Identify special clinical scenarios**—such as pediatric disease, erythrodermic presentations, refractory disease, and comorbid conditions—and adapt management strategies accordingly.
- **Incorporate multidisciplinary perspectives** (dermatology, hematology/oncology, pathology, radiation oncology, and allied health) to improve diagnostic accuracy and coordinated care.

CME ACCREDITATION

RCPSC Accreditation Statement

The Royal College of Physicians and Surgeons of Canada: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Dermatology Association. You may claim a **maximum number of 18.25 hours**.

AMA Accreditation Statement

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to *AMA PRA Category 1 Credits™*. More information on the process to convert Royal College MOC credit to AMA credit can be found on the AMA EdHub website.

European Union Medical Specialists Accreditation Statement

Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC®.

German Medical Association Accreditation Statement

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the German Medical Association, Royal College MOC Section 1 credits are deemed to be substantively equivalent to GMA CPD credits.

SPONSOR ACKNOWLEDGEMENT

This program has received an educational grant from the following organizations:

Platinum Sponsors

Kyowa Kirin

Therakos LLC

Gold Sponsor

Citius Oncology

Silver Sponsors

Bausch Health, Canada Inc.

Helsinn

Pfizer Canada


Supporting Sponsors

Dren Bio

HAC Pharma

SciTech Development

SecuraBio



ISCL 2026 LIFETIME ACHIEVEMENT AWARDEES

Join us as the ISCL Lifetime Achievement Awardees are recognized for their outstanding contribution to the science and care of patients with cutaneous lymphomas.

Award Session

Friday, June 26, 2026 | 12:15 - 12:30 | *Montréal Ballroom (11th Floor)*



Lorenzo Ceroni, MD



Youn H. Kim, MD




PLENARY AND SYMPOSIA INFORMATION

GUEST LECTURES

HERSCHEL S. ZACKHEIM LECTURE

The Herschel Zackheim Lectureship was established to honor Herschel Zackheim (1914-2009), a clinical professor emeritus at University of California San Francisco, who pioneered the discovery of treatments for patients with cutaneous lymphoma. The Lectureship recognizes and honors a clinician and/or researcher who has been a significant contributor to advancing the science and understanding of lymphoma-related biology, has contributed research that has or will be expected to improve treatment for lymphoma patients, and has outstanding leadership qualities.



Thomas S. Kupper, MD

*Chair Emeritus, Department of Dermatology, Brigham and Women's Hospital
Chair, Department of Dermatology, Dana-Farber Cancer Institute
Thomas B. Fitzpatrick Professor, Harvard Medical School*

40 Years of Research on Skin Immunity

Thursday, June 25 | 13:30 - 14:20 | [Montréal Ballroom \(11th Floor\)](#)

PLENARY LECTURE



Jason Hipp, MD, PhD

CEO, JDH Consulting, Bethesda, USA

Advances in Computational/Digital Pathology and AI in the Diagnosis of Cancer and Prediction of Prognosis

Friday, June 26 | 08:15 - 09:00 | [Montréal Ballroom \(11th Floor\)](#)

ACCREDITED SYMPOSIA

**Plated lunch will be served. Attendance is limited and based on first arrival for HCPs.*

Thursday, June 25 | 12:05 - 13:20

Fortifications, 9th Floor

The Importance of Durability of Response in Managing CTCL

This symposium was co-developed by the International Society for Cutaneous Lymphomas with Therakos LLC and was planned to achieve scientific integrity, objectivity and balance.

Moderator: Dr. Ivan Litvinov, *Dermatology, McGill University, Montréal, Canada*

Speakers: Prof. Julia Scarisbrick, *University of Birmingham, Birmingham, United Kingdom*

Prof. Jan Nicolay, *University Medical Center Mannheim, Heidelberg University, Germany*

Friday, June 26 | 12:40 - 13:55

Fortifications, 9th Floor

Bridging the gap: Advancing diagnosis and management of CTCL through collaborative multidisciplinary care

This symposium was co-developed by the International Society for Cutaneous Lymphomas with Kyowa Kirin and was planned to achieve scientific integrity, objectivity and balance.

Moderator: Dr. Ivan Litvinov, MD, PhD, *McGill University, Montréal, Canada*

Panel Members: Dr. Alejandro Gru, MD, *Columbia University Irving Medical Center, New York, USA*

Dr. Steven M. Horwitz, MD, *Memorial Sloan Kettering Cancer Center, New York, USA*

Prof. Julia Scarisbrick, MBChB, MD, *University of Birmingham, Birmingham, United Kingdom*

Patient – Randy Gaw



PROGRAM AT A GLANCE

See full session title in Detailed Program

PRE CONGRESS DAY – June 24, 2026		
12:00 - 18:00	Speaker Service Centre	Ville Marie B (9th Floor)
13:00 - 14:00	USCLC Board Meeting	McGill (8th Floor)
14:00 - 15:30	ISCL Board Meeting	Ramzay (8th Floor)
15:00 - 18:00	Registration	Montréal Foyer (11th Floor)
15:30 - 16:30	EORTC Board Meeting	McGill (8th Floor)
19:00 - 21:30	ISCL Board of Directors Dinner	L'Auberge Saint-Gabriel (offsite)

DAY ONE – June 25, 2026		
06:30 - 17:30	Registration / Speaker Service Centre	Montréal Foyer (11th Floor) / Ville Marie B (9th Floor)
07:00 - 08:00	Breakfast / Posters in Exhibit Hall	Grande Place (8th Floor)
07:00 - 20:00	Exhibits Open	Grande Place (8th Floor)
08:15 - 08:30	Welcome & Announcements	Montréal Ballroom (11th Floor)
08:35 - 10:00	Session 1A: New biomarkers for predicting outcome in CTCL	Montréal Ballroom (11th Floor)
	Session 1B: From Novel Topicals to Real-world Outcomes	Fortifications (9th Floor)
10:00 - 10:40	Coffee Break / Posters in Exhibit Hall	Grande Place (8th Floor)
10:40 - 12:00	Session 2: Risk, Disparities, and Prognostic Determinants in CTCL	Montréal Ballroom (11th Floor)
12:00 - 13:15	Lunch / Posters in Exhibit Hall	Grande Place (8th Floor)
12:05 - 13:20	Accredited Symposium: The Importance of Durability of Response in Managing CTCL <i>(plated lunch served)</i>	Fortifications (9th Floor)
13:30 - 14:20	Herschel S. Zackheim Lecture — Thomas Kupper	Montréal Ballroom (11th Floor)
14:30 - 15:50	Session 3A: T cells Gone Rogue: Single-Cell, Spatial, and Molecular Frontiers in CTCL	Montréal Ballroom (11th Floor)
14:30 - 15:30	Session 3B: Optimizing Mogamulizumab Therapy in CTCL: Real-World Evidence	Fortifications (9th Floor)
15:40 - 17:20	Session 4B: Integrating immune profiling with genomics to predict therapy response	Fortifications (9th Floor)
16:00 - 17:20	Session 4A: Contemporary Advances in CTCL	Montréal Ballroom (11th Floor)
17:30 - 18:30	Poster Session—even number poster standby	Grande Place (8th Floor)
18:00 - 20:00	Welcome Reception	Grande Place (8th Floor)

DAY TWO – June 26, 2026		
06:30 - 17:30	Registration / Speaker Service Centre	Montréal Foyer (11th Floor) / Ville Marie B (9th Floor)
07:00 - 08:00	Breakfast / Posters in Exhibit Hall	Grande Place (8th Floor)
07:00 - 18:30	Exhibits Open	Grande Place (8th Floor)
08:15 - 09:00	Invited Plenary: Jason Hipp	Montréal Ballroom (11th Floor)
09:05 - 10:15	Session 5: Cutaneous Lymphoma International Consortium: Together we can	Montréal Ballroom (11th Floor)
10:15 - 10:55	Coffee Break / Posters in Exhibit Hall	Grande Place (8th Floor)
10:55 - 12:15	Session 6: Novel Targets for CTCL Treatments	Montréal Ballroom (11th Floor)
12:15 - 12:30	Award Session	Montréal Ballroom (11th Floor)
12:30 - 13:55	Lunch / Posters in Exhibit Hall	Grande Place (8th Floor)
12:40 - 13:55	Accredited Symposium: Bridging the gap: Advancing diagnosis and management of CTCL through collaborative multidisciplinary care (plated lunch served)	Fortifications (9th Floor)
14:05 - 15:20	Session 7A: Young Investigators Presentations	Montréal Ballroom (11th Floor)
	Session 7B: “The Great Transformation”: LCT and predicting CTCL outcomes	Fortifications (9th Floor)
15:30 - 16:30	Session 8A: More Than Skin Deep: Patient Perspectives	Montréal Ballroom (11th Floor)
16:10 - 17:20	Session 8B: Evolving Perspectives in CTCL	Fortifications (9th Floor)
17:30 - 18:30	Poster Session—odd number poster standby	Grande Place (8th Floor)
18:30 - 19:30	Canadian Skin Lymphoma Network Meeting (by invitation)	Fortifications Ballroom (9th Floor)
19:00 - 22:30	6WCCL Gala Dinner (prepaid ticket required)	Montréal Ballroom (11th Floor)

DAY THREE – June 27, 2026		
07:00 - 15:00	Registration	Montréal Foyer (11th Floor)
07:00 - 13:00	Speaker Service Centre	Ville Marie B (9th Floor)
07:15 - 08:15	Breakfast / Posters in Exhibit Hall	Grande Place (8th Floor)
07:15 - 11:00	Exhibits Open	Grande Place (8th Floor)
08:15 - 10:15	Session 9A: Old Treatments Performing New Tricks	Montréal Ballroom (11th Floor)
	Session 9B: Patient Case Viewing and Discussions	Fortifications (9th Floor)
10:15 - 10:55	Coffee Break / Posters in Exhibit Hall	Grande Place (8th Floor)
10:55 - 12:25	Session 10: Debates	Montréal Ballroom (11th Floor)
12:25 - 12:55	ISCL Assembly Meeting & Awards	Montréal Ballroom (11th Floor)
12:55 - 13:55	Lunch	Montréal Foyer (11th Floor)
14:05 - 15:30	Session 11: Best of Congress	Montréal Ballroom (11th Floor)
15:30 - 15:45	Closing Remarks	Montréal Ballroom (11th Floor)

DETAILED PROGRAM

JUNE 25 THURSDAY DAY-BY-DAY PROGRAM	06:30 - 17:30	REGISTRATION <i>Montréal Ballroom Foyer (11th Floor)</i>
	07:00 - 08:00	BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL <i>Grande Place (8th Floor)</i>
	07:00 - 20:00	EXHIBITS OPEN <i>Grande Place (8th Floor)</i>
		Welcome & Announcements <i>Montréal Ballroom (11th Floor)</i>
	08:15 - 08:30	6WCCL Co-Chairs: Julia Scarisbrick, Ivan Litvinov
	08:35 - 10:00	Session 1A <i>Montréal Ballroom (11th Floor)</i>
		Primary Chair: Steven M. Horwitz Co-Chairs: Maxime Battistella, Alison Moskowitz
		New biomarkers for predicting outcome in CTCL
		Learning Objectives: At the end of this session, participants will be able to: 1. Apply new biomarkers to understanding of prognosis in CTCL 2. Clarify relationship of dupilumab and risk of CTCL progression
	08:35	Introduction – Steven M. Horwitz
	08:40	Evaluation of TRBC1 immunohistochemistry versus high-throughput sequencing of TCRB gene for clonality assessment in cutaneous T-cell lymphomas Andy Li, Service de Dermatologie, Hôpital Saint-Louis, APHP, Paris, France
	08:50	Unraveling the nature of T-cell clones of uncertain significance in cutaneous T-cell lymphomas Safa Najidh, Stanford University, Palo Alto, USA; Leiden University Medical Center, Leiden, Netherlands
	09:00	The Genomic Landscape of Mycosis Fungoides: Therapy-Associated UV Mutagenesis and Oncogenic JUNB A282V Mutation Pan Lai, Dept. of Dermatology and Venereology, Peking University First Hospital, Beijing, China
	09:10	Distinct Molecular Signatures as Predictors of Early Mortality in Advanced Mycosis Fungoides Pablo L. Ortiz-Romero, Hospital Universitario 12 de Octubre, Madrid, Spain
09:20	Head and Neck Lesions as Sentinel Clinical Features of Dupilumab-Associated Cutaneous T Cell Lymphoma Yu Xiao, Peking University First Hospital, Beijing, China	
09:30	Dupilumab Accelerates T-Cell Lymphoma via A20-Deficient NF-κB Signaling and STAT3/5 Amplification Mingjia Li, Peking University First Hospital, Beijing, China	
09:40	Loss of fibroblast interaction with malignant T-cell clones is associated with aggressive CTCL behavior across CD4+, CD8+ and TCR-γδ+ malignant phenotypes Abigail Fleischli, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA	
09:50	Q&A / Panel Discussion	

JUNE 25 THURSDAY DAY-BY-DAY PROGRAM	08:35 - 10:00	Session 1B <i>Fortifications Ballroom (9th Floor)</i>
	Primary Chair: Tomomitsu Miyagaki Co-Chairs: Antonio Cozzio, Julia Dai	
	From Novel Topicals to Real-world Outcomes	
	Learning Objectives:	
	At the end of this session, participants will be able to:	
	1. Apply emerging clinical trial data on novel topical therapies to the management of early-stage cutaneous T-cell lymphoma.	
	2. Analyze long-term clinical trajectories and relapse patterns in indolent B-cell lymphomas and CD4+ LPD based on large-scale cohort studies and real-world evidence.	
	3. Identify key risk factors and complications, such as second primary malignancies and folliculotropism, to improve long-term survivorship care.	
	08:35	Introduction – Tomomitsu Miyagaki
	08:40	Interim Results for FLASH2: A Confirmatory Phase 3 Study of Topical HyBryte™ Activated by Visible Light for Cutaneous T-Cell Lymphoma Ellen J. Kim, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
08:50	A pilot study to assess safety and efficacy of tofacitinib 2% cream in the treatment of early-stage mycosis fungoides Julia Dai, University of Texas MD Anderson Cancer Center, Houston, USA	
09:00	Treatment Outcomes and Frequent Relapsers in Primary Cutaneous Indolent B-Cell Lymphomas: A 213-Patient Single-Center Cohort Study Silvia Alberti-Violetti, University of Milan; SC Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy	
09:10	Folliculotropism and Infection-Associated Outcomes in Cutaneous T-Cell Lymphoma Toan Bui, Johns Hopkins University, Baltimore, USA	
09:20	The risk of developing second primary malignancies in patients with cutaneous lymphomas Lauren Banner, Thomas Jefferson University, Philadelphia, USA	
09:30	Real-world outcomes of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder in a UK supra-regional cutaneous lymphoma centre Neenu Sebastian, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom	
09:40	Clinical Outcomes in Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified Robert Stuver, Memorial Sloan Kettering Cancer Center, New York, USA	
09:50	Q&A / Panel Discussion	
10:00 - 10:40	MORNING BREAK AND POSTER VIEWING IN EXHIBIT HALL <i>Grande Place (8th Floor)</i>	

10:40 - 12:00

Session 2 | Montréal Ballroom (11th Floor)

Primary Chair: Larisa Geskin
Co-Chairs: Pamela B. Allen, Sima Rozati

Risk, Disparities, and Prognostic Determinants in Cutaneous T-Cell Lymphoma

Learning Objectives:

At the end of this session, participants will be able to:

1. Identify clinical and biologic high-risk features in early-stage mycosis fungoides and Sézary syndrome.
2. Analyze racial, ethnic, and socioeconomic disparities affecting diagnosis, disease severity, and outcomes in CTCL.
3. Apply emerging diagnostic and biologic tools to improve risk stratification and promote equitable care in patients with CTCL.

10:40 Introduction – [Larisa Geskin](#)

10:45 Identifying High-Risk Early-Stage Mycosis Fungoides: Prognostic Insights from the PROCLIPI Cohort

[Julia J. Scarisbrick, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom](#)

10:55 Racial Differences in Prognosis in Mycosis Fungoides and Sézary Syndrome: Analysis from the BEACON (Building an Equitable and Collaborative Oncology Network)-CTCL Cohort

[Pamela B. Allen, Winship Cancer Institute of Emory University, Atlanta, USA](#)

11:05 Colour Lines in Cancer? Exploring race as determinant of Cutaneous T-Cell Lymphoma outcomes, using the global PROCLIPI cohort

[Abraham E. Bashir, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom](#)

11:15 Racial and Ethnic Disparities in T-Cell Receptor Beta Repertoire in Cutaneous T-Cell Lymphoma

[Liliana L. Crisan, City of Hope Comprehensive Cancer and Beckman Research Institute, Duarte, USA](#)

11:25 Bridging Racial Disparities in Mycosis Fungoides Diagnosis Through Dermoscopy

[Hadar K. Shimshon, Memorial Sloan Kettering Cancer Center; Downstate University of New York Downstate Health Sciences University, New York, USA](#)

11:35 Mycosis Fungoides in the Pediatric Population in Chile: A Retrospective Study

[Rocío Millán, Pontificia Universidad Católica de Chile, Santiago, Chile](#)

11:45 Area Deprivation and Disease Severity in Adult Patients with Cutaneous T-Cell Lymphoma

[Kofi Owusu-Ansah, University of Wisconsin, Madison, USA](#)

11:55 Q&A / Panel Discussion

12:00 - 13:15 **LUNCH AND POSTER VIEWING IN EXHIBIT HALL** | *Grande Place (8th Floor)*

12:05 - 13:20 **ACCREDITED SYMPOSIUM (WITH LUNCH)** | *Fortifications Ballroom (9th Floor)*

The Importance of Durability of Response in Managing CTCL

This symposium was co-developed by the International Society for Cutaneous Lymphomas with Therakos LLC and was planned to achieve scientific integrity, objectivity and balance.

**Plated lunch will be served. Attendance is limited and based on first arrival for HCPs.*

Moderator: Ivan Litvinov, MD, McGill University, Montréal, Canada

Speakers: Julia Scarisbrick, MBChB, MD, University of Birmingham, Birmingham, United Kingdom
Jan Nicolay, University Medical Center Mannheim, Heidelberg University, Germany

Learning Objectives:

At the end of this session, participants will be able to:

1. Recognize clinical trial data and real-world evidence evaluating durability-related endpoints across systemic treatment options, with a particular focus on time to next treatment (TTNT) as a pragmatic and clinically meaningful measure of long-term benefit.
2. Outline how TTNT captures both treatment effectiveness and tolerability in routine clinical practice.
3. Evaluate the role of TTNT in treatment sequencing, long-term management strategies, and patient-centric decision-making in advanced CTCL.

13:30 - 14:20 **PLENARY: HERSCHEL S. ZACKHEIM LECTURESHIP** | *Montréal Ballroom (11th Floor)*

Primary Chairs: Julia Scarisbrick,
Steven Horwitz

40 Years of Research on Skin Immunity

Thomas S. Kupper, MD
Chair Emeritus, Dept. of Dermatology, Brigham and Women's Hospital
Chair, Dept. of Dermatology, Dana-Farber Cancer Institute
Thomas B. Fitzpatrick Professor, Harvard Medical School, Boston, USA

14:30 - 15:50 **Session 3A** | *Montréal Ballroom (11th Floor)*

Primary Chair: Joan Guitart
Co-Chairs: Adele de Masson,
Robert Gniadecki

T cells Gone Rogue: Single-Cell, Spatial, and Molecular Frontiers in CTCL

Learning Objectives:

At the end of this session, participants will be able to:

1. Describe the lesion-specific immune, stromal, and microbiomic landscapes of Mycosis Fungoides as revealed by single-cell proteomic, transcriptomic, and multi-omics approaches.
2. Integrate emerging data on T-cell clonal dynamics, checkpoint-dominated microenvironments, and immunosuppressive mechanisms to better understand disease progression and treatment response in CTCL.
3. Apply novel biomarkers and AI-based tools — including deep-learning T-cell recognition and molecular profiling of treatment-exposed lesions — to inform prognosis and therapeutic decision-making in Mycosis Fungoides.

JUNE 25 THURSDAY DAY-BY-DAY PROGRAM	14:30	Introduction – Joan Guitart
	14:35	Single-cell proteomic and transcriptomic profiling of lesion-specific aberrant T cell states and checkpoint-dominated microenvironment of Mycosis Fungoides Eleni-Kyriaki Vetsika, Department of Basic and Clinical Sciences, Medical School, University of Nicosia, UNIC Athens, Greece
	14:45	Deep-learning based T-cell Recognition and Automated Clone Estimation in early-stage Mycosis Fungoides: a proof of concept study (TRACE-MF) Pieter A. Valkema, Leiden University Medical Center, Leiden, Netherlands
	14:55	Single-cell profiling of advanced-stage mycosis fungoides reveals distinct immune and stromal responses in tumor versus erythrodermic lesions Patrick Brunner, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA
	15:05	Integrated Transcriptomic and Microbiomic Profiling of Keratinocytes in Erythrodermic Cutaneous T-cell Lymphoma Identifies Distinct Epidermal-microbial Patterns Katherine De Jong, Northwestern University, Chicago, USA
	15:15	The Role of CD84 (SLAMF5) in the Immunosuppressive Tumor Microenvironment of CTCL Laura C. Schultz, Div. of Dermatology; Dept. of Pathology, City of Hope, Duarte, USA
	15:25	Lesion-specific immune and clonal reprogramming drives Chlormethine gel response and treatment-associated dermatitis in Mycosis Fungoides Evangelia Papadavid, Centre of Excellence for Rare Diseases-Cutaneous Lymphoma, ERN-EuroBloodNet, Second Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, Greece
	15:35	Molecular analysis of irradiated cutaneous T-cell lymphoma tumors suggests markers associated with response and risk of recurrence Eleanor Ostroff, Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, USA
	15:45	Q&A / Panel Discussion
	14:30 - 15:30	
Primary Chair: Pietro Quaglino Co-Chairs: Barbara Pro, Kevin Imrie, Shamir Geller		Optimizing Mogamulizumab Therapy in Cutaneous T-Cell Lymphomas: Real-World Evidence, Safety, and Long Term Outcomes
Learning Objectives:	<p>At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Evaluate real-world evidence on the effectiveness of mogamulizumab in patients with mycosis fungoides and Sézary syndrome, including comparative outcomes versus clinical trial evidence and standard therapies. 2. Assess management strategies associated with mogamulizumab treatment, including retreatment following adverse events such as drug-related rash. 3. Interpret long-term outcomes and treatment sequencing strategies, including discontinuation and retreatment approaches, to inform clinical decision-making in relapsed or refractory disease. 	

14:30	Introduction – Pietro Quaglino
14:35	Real-world use of Mogamulizumab: final analysis of the “FIL-MOGA” study by the Italian Lymphoma Foundation (FIL) Gabriele Rocuzzo, Department of Medical Sciences, Section of Dermatology, University of Turin, Italy
14:45	Patients with Mogamulizumab-associated rash can be safely retreated with Mogamulizumab with durable remissions: A single center experience Amy Liao, Washington University School of Medicine, St. Louis, USA
14:55	“Moga-Stop” Study: extended follow-up of patients with Sézary syndrome treated with mogamulizumab after treatment discontinuation, excluding for progression Marie Beylot-Barry, CHU Bordeaux, Bordeaux Cedex, France
15:05	Overall survival in patients with mycosis fungoides or Sézary syndrome in Denmark: comparative effectiveness of mogamulizumab versus standard of care Lena Specht, Dept. of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; Dept. of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
15:15	Outcomes in relapsed/refractory mycosis fungoides or Sézary syndrome from the MAVORIC trial mogamulizumab arm versus a real-world Australian cohort receiving vorinostat H. Miles Prince, Peter MacCallum Cancer Centre, Melbourne, Australia
15:25	Q&A / Panel Discussion
16:00 - 17:20 Session 4A <i>Montréal Ballroom (11th Floor)</i>	
Primary Chair: Rudolf Stadler Co-Chairs: Neda Nikbakht, Swaminathan Iyer Contemporary Advances in Cutaneous T-Cell Lymphomas: New Frontiers in Cutaneous Lymphoma Diagnosis and Prognosis	
Learning Objectives:	At the end of this session, participants will be able to: 1. Apply recent clinico-pathological and prognostic insights (e.g. lesional BSA thresholds, TFH phenotype, co-occurring lymphomas) to refine the diagnosis and risk stratification of cutaneous T-cell lymphomas in daily practice. 2. Integrate emerging tools, such as multiparameter flow cytometry, digital whole-slide image analysis and targeted genomics, to improve the classification and monitoring of primary cutaneous lymphomas. 3. Clarify how novel clinical entities and ‘borderline’ presentations beyond classical mycosis fungoides impact therapeutic decision-making and recommendations for patient follow-up.
16:00	Introduction – Rudolf Stadler
16:05	Presentation with confluent erythema not reaching 80% body surface area is associated with advanced stage disease and has worse outcome than classical MF in the early stages Julia J. Scarisbrick, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom



16:15	Cutaneous flow cytometry: 10 years of experience from a single center Emmanuella Guenova, Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University, Linz, Austria
16:25	Reproducible Cohort Generation and Whole-Slide Learning for Cutaneous T-Cell Lymphoma and Related Lymphoproliferative Disorders Melissa Pulitzer, Memorial Sloan Kettering Cancer Center, New York, USA
16:35	Investigating the Genetic Landscape of Primary Cutaneous Lymphomas and Lymphoproliferative Disorders with T Follicular Helper Cell Phenotype (PCL-TFH) Ziba Rahbar, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
16:45	Co-occurring Chronic Lymphocytic Leukemia in Mycosis Fungoides/Sézary Syndrome: Retrospective Analysis Julia Dai, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, USA
16:55	Non-alpha/beta T-cell lymphoma: a single Centre experience on gamma/delta and TCR-silent subsets Giorgio Alberto Croci, University of Milan; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
17:05	Mycosis fungoides with a gamma-delta immunophenotype: do they differ from epidermotropic primary cutaneous gamma-delta T-cell lymphoma? Eleanor B. Ostroff, Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, USA
17:15	Q&A / Panel Discussion

15:40 - 17:20

Session 4B | Fortifications Ballroom (9th Floor)

Primary Chair: Christiane Querfeld
Co-Chairs: Alejandro Gru, Denis Miyashiro

Integrating immune profiling with genomics to predict therapy response

Learning Objectives:

At the end of this session, participants will be able to:

1. Describe how immune profiling of blood and skin informs disease biology and treatment response in CTCL.
2. Integrate genomic and clonality-based biomarkers into assessment of disease burden and therapeutic monitoring.
3. Apply emerging biomarker strategies to predict and evaluate response to mogamulizumab and other targeted therapies in CTCL.

15:40 Introduction – **Christiane Querfeld**

15:45 Functional Immune States of Blood and Skin Microenvironment Predict Mogamulizumab Response in Sézary Syndrome

Hélène Moins-Teisserenc, Institut de Recherche Saint-Louis, Paris, France

JUNE 25 THURSDAY DAY-BY-DAY PROGRAM	15:55	Targeted sequencing in patients with relapsed/refractory mycosis fungoides or Sézary syndrome treated with mogamulizumab in the MOGA-2MG-Q4W clinical trial Christiane Querfeld, City of Hope National Medical Center, Beckman Research Institute, Duarte, USA
	16:05	Rapid and Durable Blood Remission in CTCL Using Mogamulizumab: B2 as a Surrogate Marker Yenny Angela, University Clinic of Dermatology, Venerology, Allergology und Phlebology Skincancer Center Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany
	16:15	Distinct genomic profiling of folliculotropic mycosis fungoides: integrated data of whole genome sequencing and single-cell spatial transcriptomics Woo Jin Lee, Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
	16:25	Non-JAK-Family Gene Fusions in Cutaneous T-cell Lymphoma Highlights Genetic Diversity and Potential Therapeutic Targets Haiming Tang, Memorial Sloan Kettering Cancer Center, New York, USA
	16:35	Evaluation of TRBC1-based Clonality to Quantitate Blood Involvement in Cutaneous T Cell Lymphoma Katherine De Jong, Northwestern University, Chicago, USA
	16:45	Characterization of adult T-cell leukemia/lymphoma patients with specific skin lesions in a tertiary dermatological service in Brazil Denis Miyashiro, Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil
	16:55	Baseline macrophage states determine immune reprogramming trajectories and clinical response to extracorporeal photopheresis in Sézary syndrome Oleg Akilov, University of Pittsburgh School of Medicine, Pittsburgh, USA
	17:05	Molecular-based Reconsideration of Classification of Primary Cutaneous CD30-positive Lymphoproliferative Disorders Yamato Suemitsu, Memorial Sloan Kettering Cancer Center, New York, USA
	17:15	Q&A / Panel Discussion
	17:30 - 18:30	POSTER SESSION WALK IN EXHIBIT HALL Grande Place (8th Floor)
Primary Chair and Poster Walk Leader: Paula Enz	Even-numbered poster authors stand-by Best of Posters – Dr. Paula Enz will review selected posters in Beaver Hall Room next to exhibits	
18:00 - 20:00	WELCOME RECEPTION Grande Place (8th Floor)	

JUNE 26 FRIDAY DAY-BY-DAY PROGRAM	06:30 - 17:30 REGISTRATION <i>Montréal Ballroom Foyer (11th Floor)</i>	
	07:00 - 08:00 BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL <i>Grande Place (8th Floor)</i>	
	07:00 - 18:30 EXHIBITS OPEN <i>Grande Place (8th Floor)</i>	
	08:15 - 09:00 INVITED PLENARY SPEAKER <i>Montréal Ballroom (11th Floor)</i>	
	Primary Chairs: Steven M. Horwitz, Julia Scarisbrick	Advances in Computational/Digital Pathology and AI in the Diagnosis of Cancer and Prediction of Prognosis
	Jason Hipp, MD, PhD CEO JDH Consulting, Bethesda, USA	
	09:05 - 10:15	Session 5 <i>Montréal Ballroom (11th Floor)</i>
	Primary Chair: Youn H. Kim Co-Chairs: Marie Beylot-Barry, Rein Willemze	Cutaneous Lymphoma International Consortium: Together we can
	Learning Objectives:	At the end of this session, participants will be able to: 1. Appreciate that international collaborations are feasible and productive in generating large datasets in rare lymphomas 2. Recognize meaningful prognostic factors and treatment profiles and impact in CTCL utilizing international collective data
	09:05	Introduction – Youn H. Kim
09:10	Building on CLIPI: Deeper Dive into Advanced Stage Subset Youn H. Kim, Stanford University, School of Medicine, Stanford, USA	
09:30	Treatment patterns in early-stage Mycosis Fungoides: a 10-Year update from the PROCLIPI study Gabriele Rocuzzo, Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy	
09:40	Navigating Therapeutic Complexity in Advanced-Stage MF/SS: Real-World Insights from the PROCLIPI Study Abraham E. Bashir, University Hospitals Birmingham NHS Foundation Trust; University of Birmingham, Birmingham, United Kingdom	
09:50	Blood Tumor Burden Refines Prognostication: Validation of PROCLIPI for Advanced Cutaneous Lymphoma in a Chinese Cohort Zhuojing Chen, Dept. of Dermatology and Venereology, Peking University First Hospital, Beijing, China	

JUNE 26 FRIDAY DAY-BY-DAY PROGRAM	10:00	How Big Is Big Enough? The Potential for Imaging-derived Quantitative Thresholds for Identifying N3 Nodal Disease in CTCL using PROCLIPI <i>Abraham E. Bashir, University Hospitals Birmingham NHS Foundation Trust; University of Birmingham, Birmingham, United Kingdom</i>
	10:10	Q&A / Panel Discussion
	10:15 - 10:55	MORNING BREAK AND POSTER VIEWING IN EXHIBIT HALL <i>Grande Place (8th Floor)</i>
	10:55 - 12:15	Session 6 Montréal Ballroom (11th Floor) Novel Targets for CTCL Treatments
		Primary Chair: Martine Bagot Co-Chairs: Michael Khodadoust, Auris Huen
	Learning Objectives:	At the end of this session, participants will be able to: 1. Identify and validate novel targets for the treatment of cutaneous T cell lymphoma. 2. Clarify the use of new treatments.
	10:55	Introduction – <i>Martine Bagot</i>
	11:00	Nivolumab with duvelisib leads to repeated immune-mediated toxicities in cutaneous T-cell lymphoma (CTCL): Clinical results of ETCTN Study 10347 <i>Neha Mehta-Shah, Washington University in St. Louis, St. Louis, USA</i>
	11:10	Targeting TNFR2 with BI-1808: Immune Activation and Promising Responses in Advanced T-Cell Lymphomas <i>Stefan Barta, University of Pennsylvania Hospital, Philadelphia, USA</i>
	11:20	Dupilumab Use in Atopic Dermatitis When Cutaneous Lymphoma Is Suspected: Consensus Recommendations from the EORTC Cutaneous Lymphoma Task Force <i>Emmanuella Guenova, Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University, Linz, Austria</i>
	11:30	Updated Clinical Data from the Phase 1 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody in Patients with Relapsed/Refractory Cytotoxic T/NK cell Lymphomas <i>Swaminathan Iyer, MD Anderson Cancer Center, Houston, USA</i>
	11:40	Mycosis fungoides-exosomes mediate reprogramming of tumor-associated macrophages via a novel mechanism of CD47- SIRPα checkpoint interaction <i>Lilach Moyal, Rabin Medical Center, Petach Tikva, Israel; Tel Aviv University, Tel Aviv, Israel</i>
	11:50	Preliminary results in a First-in-Human Trial of ST-001 nanoFenretinide in Previously Treated Cutaneous T-cell Lymphoma <i>Oleg Akilov, University of Pittsburgh School of Medicine, Pittsburgh, USA</i>
12:00	Cutaneous outcomes associated with nemolizumab use in patients with cutaneous T-cell lymphoma: a case series <i>Krithika Nayudu, Medical College of Georgia, Augusta, USA</i>	
12:10	Q&A / Panel Discussion	

12:15 - 12:30

AWARD SESSION | *Montréal Ballroom (11th Floor)*

Primary Chairs:
Julia Scarisbrick,
Steven M. Horwitz

Special Award

Lifetime Achievement Award: Youn H. Kim, MD
Lifetime Achievement Award: Lorenzo Cerroni, MD

12:30 - 13:55 LUNCH AND POSTER VIEWING IN EXHIBIT HALL | *Grande Place (8th Floor)*

12:40 - 13:55 ACCREDITED SYMPOSIUM (WITH LUNCH) | *Fortifications Ballroom (9th Floor)*

Bridging the gap: Advancing diagnosis and management of CTCL through collaborative multidisciplinary care

This symposium was co-developed by the International Society for Cutaneous Lymphomas with Kyowa Kirin and was planned to achieve scientific integrity, objectivity and balance.

**Plated lunch will be served. Attendance is limited and based on first arrival for HCPs.*

Moderator: Dr. Ivan Litvinov, MD, PhD, *McGill University, Montréal, Canada*

Panelists: Dr. Alejandro Gru, MD, *Columbia University Irving Medical Center, New York, USA*
Dr. Steven M. Horwitz, MD, *Memorial Sloan Kettering Cancer Center, New York, USA*
Prof. Julia Scarisbrick, MBChB, MD, *University of Birmingham, Birmingham, United Kingdom*
Randy Gaw, *Patient, Canada*

Learning Objectives:

By the end of this symposium, participants will be able to:

1. Recognize suspected CTCL by identifying diagnostic challenges and interpret the clinical and histopathological features of MF and SS using staging and diagnostic tools.
2. Outline effective referral pathways for suspected CTCL, enabling timely multidisciplinary collaboration while incorporating patient perspectives.
3. Apply multidisciplinary insights to assess disease and patient characteristics that inform CTCL management and treatment decisions.

JUNE 26 FRIDAY DAY-BY-DAY PROGRAM	14:05 - 15:20	Session 7A <i>Montréal Ballroom (11th Floor)</i>
	Primary Chair: Oleg Akilov Co-Chairs: Jade Cury Martins, Montserrat Molgo	
	Young Investigators Presentations: Risk, Disparities, and Disease Behavior in Cutaneous Lymphomas	
	Learning Objectives: At the end of this session, participants will be able to:	
	1. Describe epidemiologic risks and secondary malignancy patterns in patients with cutaneous lymphomas.	
	2. Recognize biologic and clinical factors, including microbial influences and phenotype, that contribute to disease severity and heterogeneity.	
	3. Interpret prognostic indicators across CTCL and related entities, including extracutaneous progression and transplant-related outcomes.	
	14:05	Introduction – Oleg Akilov
	14:10	Risk of melanoma skin cancer among patients with mycosis fungoides and Sézary syndrome. A Swedish nationwide population-based cohort study. <i>Karolina Wojewoda, Dept. of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</i>
	14:20	Staphylococcal Hemolysins Associated with Racial Disparities and Increased Clinical Severity in Cutaneous T-Cell Lymphoma <i>Amy S. Kaku, Emory University School of Medicine, Department of Dermatology, Atlanta, USA</i>
14:30	Primary Cutaneous Marginal Zone Lymphoma developing extracutaneous disease: an European Organisation For Research And Treatment Cutaneous Lymphoma Tumour Group study. <i>Lindi Korpelshoek, Dept. of Dermatology; Dept. of Pathology, Leiden University Medical Center, Leiden, Netherlands</i>	
14:40	Disease status at HSCT, including skin-limited disease, and survival in BPDCN: A retrospective, multicenter cohort study of the EORTC, Cutaneous Lymphoma Tumour Group <i>Christoph Iselin, Department of Dermatology, Lausanne University Hospital and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland</i>	
14:50	Characteristics and outcomes of cutaneous T-cell lymphoma with gamma-delta phenotype: A single-center case series <i>Stephanie K. Lin., Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, USA</i>	
15:00	Understanding Patient Experiences and Quality of Life in Cutaneous T-Cell Lymphoma Through a Patient Education and Support Meeting <i>Brigit A. Lapolla, Columbia University, New York, USA</i>	
15:10	Q&A / Panel Discussion	

14:05 - 15:20

Session 7B | *Fortifications Ballroom (9th Floor)*

Primary Chair: Yang Wang
Co-Chairs: Gizelle Popradi,
Philippe Lefrancois

“The Great Transformation”: LCT and predicting CTCL outcomes

Learning Objectives:

At the end of this session, participants will be able to:

1. Describe clinical indicators of poor outcome and progression in CTCL
2. Define the clinical and molecular features of LCT

14:05 Introduction – **Yang Wang**

14:10 Understanding The Molecular Triggers Of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Progression

Fabio Iannelli, Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy

14:20 Large Cell Transformation in Mycosis Fungoides/Sézary Syndrome: Contemporary Outcomes, Predictors, and Disparities Signal from the U.S. BEACON-CTCL Cohort

Haris Qureshi, Yale School of Medicine, New Haven, USA

14:30 International study of mycosis fungoides with large-cell transformation confirms poor outcome and reveals heterogeneity in presentation, treatment and prognosis

Belinda A. Campbell, Peter MacCallum Cancer Centre; University of Melbourne, Melbourne, Australia

14:40 Overall Survival in Transformed Mycosis Fungoides and Sézary Syndrome

Rishabh Lohray, Baylor College of Medicine, Houston, USA

14:50 Investigating the Utility of Baseline Imaging in Early-Stage Mycosis Fungoides: A retrospective analysis

Sarah M. Gonzalez, Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, USA

15:00 Central nervous system involvement in mycosis fungoides and Sézary syndrome: multicenter series of 24 cases from French Cutaneous Lymphoma Study Group

Marie Beylot-Barry, University Hospital Bordeaux, Bordeaux, France

15:10 Q&A / Panel Discussion

15:30 - 16:30

Session 8A | *Montréal Ballroom (11th Floor)*

Primary Chair: Julia Scarisbrick
Co-Chairs: Elise Olsen,
Constanze Jonak

More Than Skin Deep: Patient Perspectives In Cutaneous Lymphoma

JUNE 26 FRIDAY DAY-BY-DAY PROGRAM	<p>Learning Objectives:</p> <p>At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Identify strategies to incorporate patient perspectives into clinical decision-making and care planning. 2. Recognize the importance of patient-centered care in the management of cutaneous lymphoma and how this may elevate patient quality of life.
	<p>15:30 Introduction – Julia Scarisbrick</p>
	<p>15:35 Core Concepts to Assess Health-Related Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome in Clinical Trials: Results of two Electronic Delphi Rounds</p> <p>Jenny J. Park, Department of Dermatology, University of Washington, Seattle, USA</p>
	<p>15:45 Improved symptoms and health-related quality of life in patients with mycosis fungoides and Sézary syndrome treated with mogamulizumab in the PROSPER study</p> <p>Julia J. Scarisbrick, Centre for Rare Diseases, University Hospital of Birmingham, Birmingham, United Kingdom</p>
	<p>15:55 Using Skindex-29 and targeted instruments to assess the impact of patient factors on quality-of-life and diagnosis understanding over time in cutaneous lymphomas</p> <p>Alyssa Wu, Dept. of Pathology, Div. of Dermatology, City of Hope, Duarte, USA</p>
	<p>16:05 Patient-Reported Quality of Life Outcomes Following Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease.</p> <p>Manda D. Mootien, Guys and St Thomas, Great Maze Pond, United Kingdom</p>
	<p>16:15 Beyond Disease Control: Holistic Needs Assessment in Patients with Cutaneous Lymphoma in a Tertiary Skin Lymphoma Clinic</p> <p>Amirtha Rajasekaran, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom</p>
	<p>16:25 Q&A / Panel Discussion</p>
	<p>16:10 - 17:20</p>
	<p style="text-align: right;">Session 8B Fortifications Ballroom (9th Floor)</p>
	<p>Primary Chair: Emilia Hodak Co-Chairs: Melissa Pulitzer, Kevin Pehr</p> <p style="text-align: right;">Evolving Perspectives in Cutaneous T-Cell Lymphoma: From Traditional Histopathology to Advanced Diagnostic and Biological Insights</p>
	<p>Learning Objectives:</p> <p>At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Understand new techniques for diagnosis of cutaneous T-cell lymphoma 2. Appreciate the complexity of cutaneous T- cell lymphoma and where diagnoses may overlap.
	<p>16:10 Introduction – Emilia Hodak</p>
<p>16:15 Reduced diversity in CTCL intratumoral microbiome is associated with JAK/STAT pathway alterations, non-European ancestry, and poor survival.</p> <p>Paola Ghione, Memorial Sloan Kettering Cancer Center, New York, USA</p>	
<p>16:25 Cytotoxic hyperactivation paired with vascular dysfunction and tissue hypoxia mediates lesion self-destruction in lymphomatoid papulosis</p> <p>Patrick Brunner, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA</p>	

- 16:35 Multi-Harmonic Imaging-Based Automated Recognition of Cutaneous T-Cell Lymphoma
Yi-Chien Tsai, Kepler University Hospital, Johannes Kepler University and Dept. of Translational Immunodermatology, JKU/KUK, Linz, Austria
- 16:45 Geographic and temporal validation of a histopathology-based diagnostic prediction model for risk-stratified triage of early-stage mycosis fungoides
Anne M. Schrader, Department of Pathology, Leiden University Medical Center, Leiden, Netherlands
- 16:55 Cutaneous anaplastic large cell lymphoma (ALCL): Clinical, histopathologic, molecular review of 13 cases of primary cutaneous ALCL & cutaneous involvement of systemic ALCL
Emma Johnson, Mayo Clinic, Rochester, USA
- 17:05 Overlap: mycosis fungoides / Sézary syndrome and inflammatory dermatosis, a case series.
Giorgio Alberto Croci, University of Milan, Milan, Italy
- 17:15 Q&A / Panel Discussion

17:30 - 18:30 **POSTER SESSION WALK IN EXHIBIT HALL** | *Grande Place (8th Floor)*

Primary Chair and Poster Walk Leader: Pablo Ortiz-Romero

Odd-numbered poster authors stand-by

Best of Posters: Dr. Ortiz-Romero will review selected posters in *Beaver Hall Room* next to exhibits

18:30 - 19:30 **Canadian Skin Lymphoma Network Board Meeting** | *Fortifications (9th Floor) by invitation*

19:00 - 22:30 **CONGRESS DINNER** | *Montréal Ballroom (11th Floor)*
 Ticket purchase required



07:00 - 15:00	REGISTRATION <i>Montréal Ballroom Foyer (11th Floor)</i>
07:15 - 08:15	BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL <i>Grande Place (8th Floor)</i>
07:15 - 11:00	EXHIBITS OPEN <i>Grande Place (8th Floor)</i>
08:15 - 10:15	Session 9A <i>Montréal Ballroom (11th Floor)</i>
Primary Chair: Francine Foss Co-Chairs: Alain Rook, David Roberge Old Treatments Performing New Tricks	
Learning Objectives:	At the end of this session, participants will be able to: 1. Describe the efficacy and adverse effects of available therapeutics in the treatment of cutaneous lymphomas 2. Understand the spectrum of use of some older therapeutics in the management of cutaneous T and B cell lymphomas
08:15	Introduction – Francine Foss
08:20	Long-term outcomes after allogeneic stem cell transplantation for cutaneous T-cell lymphoma Samer A. Srour, The University of Texas MD Anderson Cancer Center, Houston, USA
08:30	Exploring the curative potential of allo-SCT in Cutaneous T-Cell Lymphoma Julia J. Scarisbrick, University Hospitals Birmingham NHS Foundation Trust; University of Birmingham, Birmingham, United Kingdom
08:40	Interferon Alfa Lives on: Real-World Use and Safety of Pegylated Interferon Alfa-2a in Cutaneous T-Cell Lymphoma Christina Cruz, University of Pennsylvania, Philadelphia, USA
08:50	Clinical Outcomes and Durability of Localized Radiation Therapy Versus Topical Steroids in Stage IA Mycosis Fungoides Sarah J. Lange, Dartmouth Geisel School of Medicine, Hanover, USA
09:00	Systematic Review and Institutional Case Series of Intralesional Rituximab for the treatment of Primary Cutaneous B-cell Lymphoma Jori Hardin, University of Calgary, Division of Dermatology, Calgary, Canada
09:10	Hands and Feet Radiation Therapy for Cutaneous T-cell lymphoma Ahmadou B. El Alaoui, Memorial Sloan Kettering Cancer Center, New York, USA
09:20	The Therapeutic Potential of PDE4 Inhibitors in Mycosis Fungoides and Sézary Syndrome: A Brief In Vitro Study Teruyoshi Hisamoto, International University of Health and Welfare Hospital, Nasu-Shiobara City, Japan; The University of Tokyo, Bunkyo-Ku, Tokyo, Japan
09:30	Management of advanced mycosis fungoides and Sézary syndrome: international consensus recommendations from EHA, EORTC-CLTG, ISCL and EBMT Pietro Quaglino, Dermatologic Clinic, University of Turin, Turin, Italy

09:40 Linking CTCL cell biology with response to mogamulizumab for therapy optimization and identification of resistance mechanisms

Jan P. Nicolay, University Medical Center Mannheim, Mannheim, Germany

09:50 Mapping the Spatial Immune Landscape in Sézary Syndrome: Insights into Moderate and Progressive Prognoses

Marie Chevalier, Leiden University Medical Center, Leiden, Netherlands

10:00 Q&A / Panel Discussion

08:15 - 10:15

Session 9B | *Fortifications Ballroom (9th Floor)*

Primary Chair: Ivan Litvinov
Co-Chairs: Ellen Kim, Jasmine Zain, Amrita Goyal

Patient Case Viewing and Discussions

Learning Objectives:

At the end of this session, participants will be able to:

1. Recognize the clinical heterogeneity of cutaneous T-cell lymphomas (CTCL) across diverse populations and presentations, including atypical and geographically influenced disease patterns.
2. Identify key diagnostic challenges in CTCL, including distinguishing rare variants (e.g., gamma-delta phenotype, CD8+ subtypes) and differentiating CTCL from mimickers such as angioedema, infections, or other malignancies.
3. Interpret unusual anatomical presentations of CTCL, including ocular, genital, and perigenital involvement, and understand their implications for diagnosis and management.
4. Apply insights from case-based learning to improve clinical reasoning, early recognition, and management strategies for rare and atypical lymphoproliferative disorders.

08:15 Introduction – *Ivan Litvinov*

08:20 Clinical Spectrum and Diagnostic Challenges of Cutaneous T-Cell Lymphomas in Ghana: a Retrospective Analysis from a Tertiary Referral Center in Accra (2015–2024)

Prince Agyemang, Eastern Regional Hospital, Koforidua, Ghana

08:30 Ocular Mycosis Fungoides: A Single Center Case Series

Rishabh Lohray, Baylor College of Medicine, Houston, USA

08:40 Recurrent bulky tumors in a post-allogeneic stem cell transplanted Mycosis Fungoides patient cleared with a single dose of pembrolizumab

Lauren Spadt, University of Virginia School of Medicine, Charlottesville, USA

08:50 New recalcitrant perigenital tumor in the setting of otherwise well-controlled Sézary syndrome

Katherine De Jong, Northwestern University, Chicago, USA

09:00 Epidermotropic cutaneous T-cell lymphoma with gamma delta immunophenotype: Four instructive cases

Jacqueline Junkins-Hopkins, Geisinger Medical Center, Danville, USA

09:10	Merkel Cell Carcinoma: A Cutaneous B-Cell Lymphoma in Disguise? <i>Ivan V. Litvinov, St. Mary's Hospital Centre, McGill University, Montréal, Canada</i>
09:20	Clinical Warburg Effect in a Primary Cutaneous Lymphoma <i>Emmanuella Guenova, Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University, Linz, Austria</i>
09:30	Cutaneous CD8+ Cytotoxic Gamma-Delta T-cell Lymphoma Mimicking Angioedema <i>Eleanor B. Ostroff, Northwestern University Feinberg School of Medicine, Chicago, USA</i>
09:40	Vulvar and Perianal CD8-Positive Lymphomatoid Papulosis: A Case for Interdisciplinary Management of Unknown Genital Lesions <i>Sarah M. Gonzalez, Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, USA</i>
09:50	CD8+ Primary Cutaneous Peripheral T-Cell Lymphoma in a 64-Year-Old Male: A Case Report and Diagnostic Insight <i>Karla Katrina T. Cajigal, Jose R. Reyes Memorial Medical Center Department of Dermatology, Manila, Philippines</i>
10:00	Q&A / Panel Discussion
10:15 - 10:55	MORNING BREAK AND POSTER VIEWING IN EXHIBIT HALL <i>Grande Place (8th Floor)</i>
10:55 - 12:25	Session 10 <i>Montréal Ballroom (11th Floor)</i>
Primary Chairs: H. Miles Prince, Maarten Vermeer, Evangelia Papadavid Challenging Assumptions in Cutaneous Lymphomas: A Debate Series	
Learning Objectives:	<p>At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Clarify evolving diagnostic boundaries in CTCL by examining expert debates on SPTCL classification, Sézary syndrome presentations, and pediatric CTCL evaluation. 2. Apply current evidence to differentiate challenging CTCL presentations, including blood involvement without erythroderma, in order to improve diagnostic accuracy and clinical decision-making. 3. Integrate prognostic indicators into the management of early-stage MF and evaluate whether treatment strategies should be modified at disease onset.
10:55	Introduction
11:00	Should SPTCL be classified as a lymphoma? – <i>Michael Girardi, Yale University, New Haven, USA</i> vs. <i>Joan Guitart, Northwestern Medicine, Evanston, USA</i>
11:20	Pediatric CTCL: Are we underdiagnosing or overdiagnosing? – <i>Chalid Assaf, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, Krefeld, Germany</i>
11:40	Should we treat early MF with poor prognostic indicators differently from the onset? – <i>Jade Cury Martins, University of São Paulo, São Paulo, Brazil</i> vs. <i>Maarten Vermeer, LUMC, Oegstgeest, Netherlands</i>

12:00 Sézary syndrome without erythroderma as the initial presentation of a T-cell lymphoma. Is it a Mycosis fungoides debuting with stage B2 – **Emmilia Hodak, Rabin Medical Center, Petah Tikva, Israel**, vs. **Pablo Ortiz-Romero, Hospital 12 de Octubre, Madrid, Spain**

12:20 Final Q&A

12:25 - 12:55 **ISCL Assembly Meeting and Awards** | *Montréal Ballroom (11th Floor)*

12:55 - 13:55 **LUNCH** | *Montréal Ballroom Foyer (11th Floor)*

14:05 - 15:30

Session 11 | *Montréal Ballroom (11th Floor)*

Primary Chairs: Emmanuella Guenova, José A. Sanches Jr., Chalid Assaf

Best of Congress

Learning Objectives:

At the end of this session, participants will be able to:

1. Summarize key advances and high-impact findings presented across multiple sessions of the Congress, as identified by expert Co-Chairs.
2. Integrate selected best-practice insights into clinical decision-making and future research directions in cutaneous lymphomas.

14:05 Introduction

14:10 - 14:35 3 best sessions – **Emmanuella Guenova, Kepler University Clinic, Linz, Austria**

14:35 - 15:00 3 best sessions – **José A. Sanches, Jr., University of São Paulo Medical School, São Paulo, Brazil**

15:00 - 15:25 3 best sessions – **Chalid Assaf, Assaf, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, Krefeld, Germany**

15:25 Q&A / Panel Discussion

15:30 - 15:45 Closing Remarks



POSTERS

CHALLENGING CASES OF CUTANEOUS LYMPHOMAS

- P01 Importance of excisional biopsy for diagnosing EBV-positive diffuse large B-cell lymphoma, not otherwise specified presenting with extensive histologic necrosis
Hamada, Toshihisa | *Department of Dermatology, International University of Health and Welfare* | Narita, Japan
- P02 From Benign to Neoplastic: Evolution of Cutaneous Lymphoid Hyperplasia into Primary Cutaneous Marginal zone lymphoma.
Enz, Paula A. | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina
- P03 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation – report of 3 cases
Guenova, Emmanuella | *Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University* | Linz, Austria
- P04 Cutaneous T-cell lymphoma developing in surgical scars post cardiac surgery
Litvinov, Ivan V. | *St. Mary's Hospital Centre, McGill University* | Montréal, Canada
- P05 Long-term Development of Multiple Keratinocyte Malignancies Following Narrowband UVB Therapy for Mycosis Fungoides
Fujii, Kazuyasu | *Kindai University Hospital* | Sakai, Japan
- P06 Granulomatous Slack Skin–Like Cutaneous T-Cell Lymphoma in a 14-Year-Old With Hodgkin Lymphoma: A Rare Pediatric Presentation
Ghafari, Ghazal | *Geisinger Health System* | Danville, USA
- P07 Langerhans cell histiocytosis (LCH) with unusual skin presentation: a dangerous mimic of erythrodermic primary cutaneous T-cell lymphoma/Sézary Syndrome
Pehr, Kevin | *Div. of Dermatology, McGill University. Lady Davis Institute for Medical Research* | Montréal, Canada
- P08 Unilesional Granulomatous Mycosis Fungoides: Case Report in a Young Patient
Reculé, Francisca | *Clinica Alemana and Universidad del Desarrollo* | Santiago, Chile
- P09 Cutaneous T-cell lymphomas linked to treatments with new biological agents and small molecules
Enz, Paula A. | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina

CLASSIFICATION / EPIDEMIOLOGY / PROGNOSTIC FACTORS

- P10 Clinicopathologic Discordance in Folliculotropic Mycosis Fungoides: Clinical Relevance and Outcome Associations
Bui, Toan | *Johns Hopkins University* | Baltimore, USA
- P11 B2 mycosis fungoides, not always Sézary
Cury Martins, Jade | *University of São Paulo* | São Paulo, Brazil
- P12 Prevalence of human T cell lymphotropic virus 1 infection in Canada
Litvinov, Ivan V. | *St. Mary's Hospital Centre, McGill University* | Montréal, Canada

- P13 Clonal Granulomatous Dermatitis Associated With Myeloid Neoplasms: A Clinicomolecular Study of 16 Patients
Battesti, Gilles | *Dermatology, Saint Louis Hospital, Paris APHP France* | Paris, France
- P14 Localised Primary Cutaneous Gamma-Delta T-Cell Lymphoma
Tee, Shang-lan | *National Skin Centre* | Singapore, Singapore
- P15 Primary Cutaneous B-Cell Lymphomas: A 13-Case Series from a Referral Center in Buenos Aires, Argentina
Enz, Paula A. | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina
- P16 Candidate Tumor Markers of Cutaneous T-cell Lymphomas Identified Through Analysis of Two Cases of Peripheral T-Cell Lymphoma, Not Otherwise Specified
Honda, Ryoma | *International University of Health and Welfare Graduate School of Medicine* | Narita, Japan
- P17 Primary Cutaneous Lymphomas and Lymphoproliferative Disorders in a Community-Based Oncology Network: Disease Spectrum and Secondary Malignancies
Walker, Christina J. | *Community Health Network* | Indianapolis, USA
- P18 Prognostic Value of Tumor Clone Frequency in Mycosis Fungoides
Nikbakht, Neda | *Department of Dermatology, Hematology, and Medical Oncology, Emory University* | Philadelphia, USA
- P19 Long-term Outcomes and Recurrence Patterns in Primary Cutaneous Marginal Zone Lymphoma and Primary Follicle Centre Lymphoma B-cell Lymphoma
Bashir, Abraham E. | *University Hospitals Birmingham NHS Foundation Trust* | Birmingham, United Kingdom
- P20 Mantle Cell Lymphoma with Cutaneous Involvement: A Systematic literature review
Babana el Alaoui, Ahmadou | *Memorial Sloan Kettering Cancer Center* | New York, USA

PATHOLOGY / BIOMARKERS / MICROENVIRONMENT

- P21 Single-cell-resolution spatial transcriptome profile and prognostic implication of cancer-associated fibroblast in early-stage mycosis fungoides
Lee, Woo Jin | *Asan Medical Center, University of Ulsan College of Medicine* | Seoul, Korea
- P22 A Scoping Review on the Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T-cell Lymphoma
Czyz, Sonia | *Dept. of Medicine, Cumming School of Medicine, University of Calgary* | Calgary, Canada
- P23 Diagnosis of Cutaneous Lymphomas by T-Cell Clonality Analysis: Comparative Effectiveness of Methods
Gorenkova, Liliya | *The National Research Centre of Haematology* | Moscow, Russia
- P24 JAK-Inhibition As A Novel Multilevel Treatment Of Cutaneous T Cell Lymphoma
Pourjafar, Mona | *Department of Clinical Medicine, The Department of Dermatology and Venereology, Aarhus University Hospital* | Aarhus, Denmark
- P25 Phenotypic switching in mycosis fungoides/Sézary syndrome patients: clinical implications and survival outcomes in four Brazilian cases
Miyashiro, Denis | *Department of Dermatology, University of São Paulo Medical School* | São Paulo, Brazil

P26 Tumor-informed ctDNA MRD monitoring correlates with cutaneous lesion evolution and PET response in stage IIB mycosis fungoides

[Rouf, Rejwana](#) | *Mount Sinai Hospital* | New York, USA

P27 Dissecting immune determinants in lesional skins of cutaneous T-cell lymphoma during Mogamulizumab therapy

[Ni, Xiao](#) | *Dept. of Dermatology, The University of Texas MD Anderson Cancer Center* | Houston, USA

QUALITY OF LIFE / PATIENT REPORTED OUTCOMES

P28 Quality-of-Life and Supportive-Care Interventions in Mycosis Fungoides and Sézary Syndrome: A Scoping Review

[Bouchi, Yazan A.](#) | *Morehouse School of Medicine* | Atlanta, USA

P30 Content Validity of Itch Patient-Reported Outcome Measures in Cutaneous T-Cell Lymphoma: A COSMIN-guided Qualitative Study

[Park, Jenny J.](#) | *Department of Dermatology, University of Washington* | Seattle, USA

P31 Overcoming barriers to bathing care for patients with cutaneous lymphoma: observations from 25 years of nursing care in an Australian quaternary referral centre.

[Buelens, Odette C.](#) | *Peter MacCallum Cancer Centre* | Melbourne, Australia

P32 Health-Related Quality of Life in Cutaneous T-Cell Lymphoma Treated With Multimodality Therapy Including Extracorporeal Photopheresis: A Latin American Experience

[Enz, Paula A.](#) | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina

P33 Quality of Life in Cutaneous T-Cell Lymphoma: Current Insights and Future Directions

[Vermeer, Maarten](#) | *LUMC, Leiden* | Leiden, Netherlands

P34 Evaluation of an educational video to support understanding of health-related quality of life for patients with cutaneous T-cell lymphoma

[Nayudu, Krithika](#) | *Medical College of Georgia* | Augusta, USA; *Mass Brigham General* | Boston, USA

THERAPEUTICS / PRECLINICAL STUDIES

P35 Treatment Outcomes and Recurrence Patterns Following Local Therapies in Primary Cutaneous Marginal Zone and Follicle Center Lymphoma

[Gonzalez, Sarah M.](#) | *Department of Dermatology, Dartmouth-Hitchcock Medical Center* | Lebanon, USA

P36 Comprehensive Characterization of DT-7012, a Highly Differentiated Anti-CCR8 Depleting Antibody in CTCL

[Sabbagh, Laurent](#) | *Kainova Therapeutics* | Montréal, Canada

P37 Post hoc analysis of a randomized, controlled, phase 2 study to assess the efficacy of chlormethine gel in patients with early-stage mycosis fungoides based on skin phototype

[Rozati, Sima](#) | *Johns Hopkins University School of Medicine* | Baltimore, USA

P38 EORTC 1820-MOGAT – Mogamulizumab Plus Total Skin Electron Beam Therapy in Patients with stage IB-IIB Cutaneous T-Cell Lymphoma

[Ortiz-Romero, Pablo L.](#) | *Hospital Universitario 12 de Octubre* | Madrid, Spain

P39 Use of Immune Checkpoint Inhibitors in Refractory Mycosis Fungoides and Sézary Syndrome: A Systematic Review

Litvinov, Ivan V. | *St. Mary's Hospital Centre, McGill University* | Montréal, Canada

P40 Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational study

Bozonnat, Alizée | *Department of Dermatology, Saint-Louis Hospital, AP-HP, INSERM U976, Université Paris Cité* | Paris, France

P41 Mogamulizumab: Real-World Experience in Heavily Treated Patients With Mycosis Fungoides and Sézary Syndrome: Durable Efficacy and Tolerability

Alabdulkareem, Ahmad | *Division of Dermatology, McGill University* | Montréal, Canada

P42 A phase 1, multicenter, prospective, first-in-human dose-escalation clinical trial of anti-CCR8 monoclonal antibody DT-7012 in patients with relapsed or refractory CTCL

Beylot-Barry, Marie | *Department of Dermatology, CHU de Bordeaux – INSERM 1312, University of Bordeaux* | Bordeaux, France

P43 BUFALLO is a novel reduced intensity conditioning regimen for the allogeneic stem cell transplantation for patients with primary cutaneous T-cell lymphomas

Gorenkova, Liliya | *The National Research Centre of Haematology* | Moscow, Russia

P44 Topical JAK Inhibitors in Early-Stage Mycosis Fungoides: A Systematic Review

Kheirmand, Kimia | *Aarhus University Hospital* | Aarhus N, Denmark

P45 Mogamulizumab treatment for mycosis fungoides in clinical practice in France: data from the ongoing multicentric prospective observational PROMED study

Beylot-Barry, Marie | *Department of Dermatology, CHU de Bordeaux – INSERM 1312, University of Bordeaux* | Bordeaux, France

P46 Combination Low-dose Radiotherapy and Topical Imiquimod May Stimulate a Systemic Anti-tumor Response in Mycosis Fungoides

De Jong, Katherine | *Northwestern University* | Chicago, USA

P47 New Onset and Rapid Progression of Cutaneous T-Cell Lymphomas in Association with Immune Checkpoint Inhibitor Therapy: A Systematic Review

Babana el Alaoui, Ahmadou | *Memorial Sloan Kettering Cancer Center* | New York, USA

LATEBREAKING

P48 Disproportionate Representation of Intellectual Disability and Higher Fitzpatrick Skin Types Among Patients Presenting with Tumor-Stage Cutaneous T-Cell Lymphoma

Lapolla, Brigit A. | *Columbia University* | New York, USA


P49 Deruxtecan-based antibody-drug conjugate targeting TCR-Vβ2 for the treatment of cutaneous T cell lymphoma

Kwang, Alexa | *Yale University* | New Haven, USA

P50 Primary cutaneous innate lymphoid lymphoma

Zhang, Yue | *Memorial Sloan Kettering Cancer Center* | New York City, USA

- P51 Epidermotropic, cytotoxic, ALK+ T-cell lymphoma: appraisal of a discrete pattern of disease
Croci, Giorgio Alberto | *University of Milan* | Milano, Italy; *Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico* | Milano, Italy
- P52 Adult T-Cell Leukemia/Lymphoma Emerging During Dupilumab Therapy for Severe Atopic Dermatitis: Should We Screen for HTLV-1?
Millán, Rocío | *Pontificia Universidad Católica de Chile* | Santiago, Chile
- P53 Adult T-Cell Leukemia/Lymphoma Mimicking Indolent Cutaneous Lymphoma: The Role of HTLV-1 and Re-biopsy in Endemic Regions
Millán, Rocío | *Pontificia Universidad Católica de Chile* | Santiago, Chile
- P54 Imaging Beyond Staging in Primary Cutaneous Marginal Zone Lymphoma: Interim Analysis of a Multi-Institutional Retrospective Study
Zhou, Maggie H. | *Columbia University Vagelos College of Physicians and Surgeons* | New York, USA
- P55 Cutaneous and peripheral T-cell lymphomas increase the risk of cardiovascular and thromboembolic events: A retrospective TriNetX cohort study
Nicolay, Jan P. | *University Medical Center Mannheim* | Mannheim, Germany
- P56 IL4R α blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides
Fuschiotti, Patrizia | *University of Pittsburgh* | Pittsburgh, USA



AUTHOR INDEX

A

Abdo, André	P25	Alaibac, Mauro S.	3B.01
Abreu, Damien	P10	Alberti Violetti, Silvia	1B.03, 3B.01, 4A.06, 7B.01, 8A.02, 8B.06, 9A.08, P51
Adamski, Henri	3B.03, P40	Alhusayen, Raed	P22
Afkhami, Michelle	2.04	Alkon, Natalia	1A.07, 3A.03
Agrawal, Shruti	8B.05	Allen, Pamela B.	2.02, 4B.08, 6.01, 7A.02, 7B.02, P28
Aguilar Neuville, Paola	4A.07	Alluri, Usha	P19
Agyemang, Prince	9B.01	Amatore, Florent	3B.03, 7B.06, P40, P45
Ajmani, Ayushya	7B.05, 9A.04, P35	Amel-Kashipaz, Rasoul	1B.06
Akatsuka, Taro	9A.07	Amitay-Laish, Iris	6.05
Akilov, Oleg	4B.02, 4B.08, 6.01, 6.04, 6.06, P56		
Akkad, Neha	2.02		
Alabdulkareem, Ahmad	P41		



Angela, Yenny	4B.03	Bazewicz, Christopher G.	P37, P54
Antunes, Stéphanie	P38	Beaven, Anne	2.02, 7B.02
Arase, Kotono	P01	Bech, Rikke	3B.04, P24, P44
Arbat, Natalia	P08	Bedano, Pablo M.	P17
Ardigò, Marco	9A.08	Bejar, Claudia	P40
Ardon, Orly	4A.03	Belousova, Irena	P43
Arkatkar, Samruddhi	7B.04	Beltraminelli, Helmut	P40
Arkin, Coral	6.05	Beltzig, Paul	9A.09
Arora, Payal	4B.02	Beltzung, F.	7A.03
Arumainathan, Arvind	8A.02	Benattar, Julian	6.05
Asrani, Roshan	P26	Benelfellah, Salma	P20
Assaf, Chalid	6.03	Bennani, Nora	6.01
Assini, Alicia	8B.01	Bens, Guido	P40
Aubin, François	P40	Bernard, Pauline	8B.03
Aung, Phyu P.	4A.04	Bernardelli, Andrea	3B.01
Ayers, Amy	2.02, 7B.04	Bernuzzi, Patrizia	3B.01
Ayzman, Ann	2.02, 7B.02	Berti, Emilio	1B.03, 4A.06, 7B.01, 8B.06, 9A.08
Aziz, Nadia	7A.02		
B			
Babana el Alaoui, Ahmadou	P20, P47	Beylot-Barry, Marie	3B.03, 7A.03, 7B.06, P40, P42, P45
Baelde, Hans J.	3A.02		
Bagot, Martine	3B.03, 4B.01, 4B.02, 6.03, 9A.08, P40, P45	Bhabha, Friyana	3B.05
Baird, Katelin	2.02	Bhatti, Safiyyah	P18
Balabanian, Karl	4B.01	Bhayani, Shahzeem	3B.02
Bandali, Tarek	6.04	Bhullar, Harmeet	3B.05
Banner, Lauren	1B.05	Biard, Lucie	P42
Baquero Rey, Jenny A.	P02, P09, P15, P32	Biderman, Bella	P23
Barta, Stefan	6.02, 7A.05, 9A.03	Bielefeld, Annette	4B.03
Bashir, Abraham E.	1B.06, 2.01, 2.03, 4A.01, 5.02, 5.03, 5.05, 7A.03, 7B.03, 8A.05, 9A.02, P19	Blanchard, Orphée	P36
Bastidas Torres, Armando N.	1A.02	Boeuf, Elodie	P36
Battesti, Gilles	4B.01, P13	Bonacina, Luigi	8B.03
Battistella, Maxime	1A.01, 4B.01, 5.05, 6.03, 7A.03, 7A.04, 8B.04, P13, P40, P42, P45	Bonnet, Nathalie	3B.03, P40
		Bosi, Alessandro	1B.03
		Bouaziz, Jean David	P13, P40
		Bouchi, Yazan A.	P28
		Boulinguez, Serge	P40
		Bozonnat, Alizée	4B.01, P13, P40
		Brammer, Jonathan	6.04

Bruey, Silvina	P15, P32
Brunet-Possenti, Florence	7B.06, P40
Brunner, Patrick	1A.07, 3A.03, 8B.02
Brussee, Siemen	3A.02, 8B.04
Buckhoree, Farrah	6.07
Buelens, Odette C.	3B.05, P31
Bui, Toan	1B.04, 2.02, P10, P54
Burke, Ryan D.	1A.02
Burks, Jared K.	P27
Burnett, Amelia	1A.07, 8B.02
Burns, Michael	3A.04, 6.06

C

Cabala, Carlos	7B.04
Cajigal, Karla Katrina T.	9B.10
Calvão, Joana	4A.02, 6.03, 9B.07, P03
Campbell, Belinda A.	3B.05, 7B.03, P31
Cantonetti, Maria	3B.01
Cardemil, Daniela	P52
Cardoso, José Carlos	4A.02, 9B.07, P03
Carlson, Kacie R.	P49
Carneiro, Ana	6.02
Carter, Joi B.	7B.05, 9A.04, 9B.09, P35
Castro, Alex	P08
Cavalloni, Chiara	3B.01
Cederquist, Gustav	9A.06
Cerroni, Lorenzo	2.01, 9A.08
Cesar, Laura	9A.03
Chang, Sung Eun	4B.04, P21
Chang, Yun-Tsan	8B.03
Chasset, François	P13, P40
Chen, Anna M.	P54
Chen, Caroline	P48
Chen, Lu	2.04, 8A.03
Chen, Yuxian	3B.05
Chen, Zhuojing	5.04

Cheng, Jinghui	1A.03
Chennareddy, Sumanth	1A.07, 8B.02
Chergui, May	9B.06
Chevalier, Marie	9A.10
Chiarle, Roberto	7B.01
Cho, Woo C	4A.04
Choi, Myoung Eun	4B.04, P21
Chraa, Dounia	P36
Chung, Jina	7A.05, 9A.03, P54
Clappier, Emmanuelle	P13
Clarke, Lauren P.	3A.07, P46
Cleveland, Joseph M.	1A.02
Climent, Fina	1A.04, 7A.03
Cohenour, Emry R.	3A.03
Colavincenzo, Maria	9B.08
Collie, Angela M.	8B.05
Colombo, Riccardo	1B.03
Comfere, Nneka I.	8B.05
Comont, Thibault	P13
Comstock, Jeanette	2.07
Cooper, Yonathan	1A.02
Copling, Sage	7B.04
Cordoba, Raul	4B.02
Cordoliani, Florence	P13
Cowan, Richard	4B.02, 6.03, 8A.02, P19, P38
Cozzio, Antonio	6.03, 7A.04
Crisan, Liliana L.	2.04, 3A.05, 8A.03
Croci, Giorgio Alberto	1B.03, 4A.06, 7A.03, 8B.06, P51
Cruz, Christina	9A.03
Cuillerot, Jean-Marie	P42
Curry, Jonathan L.	4A.04
Cury Martins, Jade	4B.07, P11, P25
Czyz, Sonia	9A.05, P22

D

D'Incan, Michel	P40
-----------------	-----

Dabaja, Bouthaina S.	7B.04, 9A.01	Duarte, Rafael Palomino	9A.08
Dagala, Ron Michael P.	9B.10	Dummer, Reinhard	9A.10
Dai, Julia	1B.02, 4A.04, 4A.05, 7B.04, 9B.02	Dumont, Maëlle	4B.01
Dalle, Stéphane	7A.04, P40, P42	Duong, Teresa	P18
Das, Jishnu	P56	Duran, George E.	1A.02
Dasgupta, Rishob	P18	Duvic, Madeleine	4A.05, 7B.04, 9A.01, 9B.02, P27
Davey, Theresa	8B.01	E	
Davis, Sian	8A.05	El Aarbaoui, Tarik	3B.03
De Jong, Katherine	3A.04, 3A.07, 4A.07, 4B.06, 9B.04, 9B.08, P46	El Alaoui, Ahmadou B.	9A.06
de Jonge, Marthe M.	8B.04	Elenitoba-Johnson, Kojo	4B.09, 8B.01
De Lorenzo, Sonya	3B.01	El-Farouk, Samira	P42
de Masson, Adèle	1A.01, 3B.03, 4B.01, 6.03, 7B.06, 9A.08, P13, P36, P40, P42	Elghawy, Omar	7A.05
de Oude, Alyssa	3A.02	Enz, Paula	P02, P09, P14, P15, P32
de Vicq de Cumplich, Marine	3B.03	Epstein-Peterson, Zachary	1B.07, 4B.05, 4B.09, 8B.01, 9A.06
de Vicq, Marie	7B.06	Eroshenkov, Daniil	P43
Dekkal, Mehdi	P45	Esler, Claire	8A.02
Delaleu, Jérémie	4B.01, 7B.06	Espeli, Marion	4B.01
Deliyannis, Eduardo	8A.05	Evans, Spencer	3A.07
Dereure, Olivier	3B.03, 7B.06, P40, P45	Evision, Felicity	2.01, 2.03, 4A.01, 5.02, 5.03, 5.05, 9A.02
DeSimone, Jennifer	1B.01, 8A.02, 9B.03, P37	Eyuboglu, Mavi D.	1A.02
Dhont, Bert	P38	F	
Di, Mengyang	6.04	Fabbri, Alberto	3B.01
Díaz de la Pinta, Francisco Javier	1A.04	Faiz, Sarah	3B.03, P40, P45
Díaz, Javier	P53	Fang, Penny	7B.04
Didier, Marie	7B.06	Farquharson, Nina	P19
Dobos, Gabor	P40	Fava, Paolo	3B.01
Doeleman, Thom	3A.02, 8B.04	Fayad, Luis	7B.04, 9A.01
Dogan, Ahmet	4A.03, 4B.05	Fei, Teng	8B.01
Donekal, Yamini	6.06	Feldman, Tatyana	P50
Donini, Oreola	1B.01	Feldmeyer, Laurence	P40
Donzel, Marie	P40	Fenaux, Pierre	P13
Downey, Camila	2.06	Feng, Lei	7B.04
		Figuera, Amalia	3B.01
		Filotico, Raffaele	3B.01

Fischer, Anne	6.01
Fleischli, Abigail	1A.07, 3A.03, 8B.02
Flowers, Christopher	7B.04
Fong, Lon Wolf	4A.04
Fontinha, Guilherme	9B.07
Foss, Francine	2.02, 7B.02, 9A.08, P49
Franchet, Christel	P36
Franck, Nathalie	P40
Frauli, Mélanie	P36
Fredeus, Björn	6.02
Friyana, Bhabha	P31
Fu, Lucy	4B.06
Fujii, Kazuyasu	P05
Fuschiotti, Patrizia	P56

G

Galaras, Alexandros	3A.06
Galati, Melissa	9B.06
Gales, Lynn	P13
Ganesan, Nivetha	8B.01
Garcia Fernandez, Maria Dolores	P36
Gaydosik, Alyxzandria	P56
Gebauer, Niklas	P55
Geller, Shamir	1B.07, 2.02, 2.05, 4B.05, 4B.09, 8B.01, 9A.06, P47, P50
Geloso, Marianela	P02, P09, P15, P32
Gertsson, Susanne	6.02
Geskin, Larisa J.	4B.02, 7A.06, 8A.02, P48, P54, P56
Ghafari, Ghazal	P06
Ghazawi, Feras M.	P12
Ghione, Paola	1B.07, 4B.05, 4B.09, 7B.02, 8B.01, 9A.06, P50
Ghosh, Shayantani	8B.03
Gibaldi, Angela	8B.01
Gillis, Maura	2.05, 9A.06, P20

Gillstedt, Martin	7A.01
Giordano, Antonio	8A.02
Girardi, Michael	7B.02, P49
Gleason, Laura	1B.05, P18
Goldaniga, Maria C.	8A.02
Goldgof, Greg	4A.03
Goldwirt, Lauriane	P42
Gonçalo, Margarida	6.03
Gonzales-Barca, Eva	9A.08
Gonzalez, Sarah M.	7B.05, 9A.04, 9B.09, P35
Gordon, Emily	7A.06, P48
Gorenkova, Liliya	P23, P43
Gorovitz, Batia	6.05
Goswami, Megahali	P27
Gotor-Rivera, Alfonso	1A.04
Goyal, Amrita,	9A.08
Granara, Martina	P02, P09, P15, P32
Grael-Brocard, Florence	P45
Grange, Florent	3B.03, 7B.06, P40, P45
Grove, Elisabeth L.	P44
Gru, Alejandro A.	4A.01, 5.05, 6.04, P54
Gschnell, Martin	9A.09
Guenova, Emmanuella	3B.03, 4A.02, 6.03, 7A.04, 8B.03, 9B.07, P03, P40
Guistiniani, Jérôme	P36
Guitart, Joan	3A.04, 3A.07, 4A.07, 4B.06, 9A.08, 9B.04, 9B.08, P46
Gunther, Jillian R.	7B.04, 9A.01
Gutzmer, Ralf	4B.03

H

Hafer, Ramsay	1B.05
Hainaut, Ewa	P40, P45
Hamada, Toshihisa	P01, P16
Han, Wei	P27
Hatzis, Pantelis	3A.06

Hansen, Signe H.	P44
Haque, Christina	P19
Hardin, Jori	9A.05, P22
Haverkos, Bradley	6.01, 6.06
Hayashi, Yuichiro	P01
Hedebo, Signe	P24
Hijal, Tarek	P04
Hisamoto, Teruyoshi	9A.07
Hock, Ye Lin	7A.04
Hodak, Emilia	6.03, 6.05, 9A.08
Holm, JoJo	3A.07, 9B.08, P46
Holmkvist, Petra	6.02
Holsapple, Earle	6.06
Honda, Ryoma	P16
Hong, Diane S.	1B.04, P54
Hong, Wan-Jen	6.04
Hooper, Madeline J.	3A.07
Horstmann, Hauke	P55
Horwitz, Steven M.	1B.07, 4B.05, 4B.09, 6.04, 8B.01, 9A.06
Hosing, Chitra	7B.04, 9A.01
Hubbeling, Harper	7A.05
Huen, Auris O.	1B.02, 2.02, 4A.04, 4A.05, 4B.02, 6.06, 7B.02, 7B.04, 9A.01, 9B.02
Hurtado, Angelly M.	P08

I

Iannelli, Fabio	7B.01
Ibatici, Adalberto	3B.01
IJsselsteijn, Marieke	9A.10
Imber, Brandon S.	1B.07, 9A.06
Ingen-Housz-Oro, Saskia	P40
Iselin, Christoph	7A.04, 8B.03
Itzykson, Raphael	P13
Iyer, Swaminathan P.	4A.04, 6.04, 7B.02, 7B.04, 9A.01

J

Jachiet, Marie	P13
Jacobsen, Eric	6.01
Jafarnia, Jordan	7B.04
Janela-Lapert, Raphaël	3B.03, P45
Jansen, Patty M.	7A.03, 8B.04
Jayawardana, Madawa	3B.05
Jedrych, Jaroslaw	P10
Jeremian, Richie	9B.06
Jeudy, Geraldine	P45
Jiang, Yi	1A.05, 1A.06
Johan, Feba	6.05
Johanna, Tischer	7A.04
Johnson, Emma	8B.05
Johnson, William	4B.05, 9A.06
Johnstone, Philippa	7B.03
Joly, Pascal	P40
Jonak, Constanze	1A.07, 3A.03, 6.03, 8B.02
Joseph, Jeff	7B.05
Jouenne, Fanélie	1A.01
Junkins-Hopkins, Jacqueline	9B.05, P06

K

Kaku, Amy S.	7A.02
Kalomeris, Taylor	4B.09
Kamali, Ali	4A.03
Kamstrup, Maria R.	3B.04
Kappenstein, Max	P55
Karagianni, Fani	3A.01, 3A.06
Karlsson, Ingrid	6.02
Karrs, Jeremiah X.	9B.09
Kaur, Harpreet	P31
Keegan, Alissa	6.04
Kempf, Werner	2.01, 6.03, 7A.03, 8B.04
Kent, Joshua	7A.06, P48
Kerckhoffs, Kelly G.	8B.04

Kers, Jesper	3A.02, 8B.04	Lapen, Kaitlyn	9A.06
Kheirmand, Kimia	P44	Lapolla, Brigit A.	7A.06, P48, P54, P56
Khodadoust, Michael S.	1A.02, 6.04	Larcher, Marie-Virginie	7A.04
Kim, Doyoung	8B.03	LaRiviere, Michael	7A.05
Kim, Ellen J.	1B.01, 7A.05, 8A.01, 9A.03, P30, P34	Larocca, Cecilia	6.07, 8A.01, P30, P34
Kim, Kunhwa	7B.04	Latkowski, Jo-Ann M.	P54
Kim, Won Seog	6.04	Latshaw, Alexandra	8B.03
Kim, Youn H.	1A.02, 1B.01, 2.01, 2.03, 4A.01, 4B.02, 5.01, 5.02, 5.03, 5.05, 6.04, 9A.02, 9A.08, P27	Lazar, Alexander J.	4A.04
King, Amber L.	9B.09	Lazcano, Rossana	4A.04
Kirsch, Ilan	1A.02	Le Corre, Yannick	3B.03, P45
Kiwan, Ahmad	7B.02	Le, Yen T.	8B.05
Klespe, Kai	9A.09	LeBlanc, Robert E.	9B.09
Koh, Youngil	6.04	Lechowicz, Mary Jo	2.02, 7A.02, P28
Kohan, Dana	P02, P09	Lee, Ji Hyun	6.04
Kondo, Ryo	P01	Lee, Joohyung	P49
Korpelshoek, L.	7A.03	Lee, Mi Woo	4B.04, P21
Kottler, Diane	7B.06, P45	Lee, Riko	2.07
Kou, Aya	P05	Lee, Woo Jin	4B.04, P21
Kremer, Noa	2.05	Lehman, Julia S.	8B.05
Kunta, Niharika	P27	Lelièvre, Hélène	P36, P42
Kupper, Thomas	6.07	Lenne, Nathalie	P36
Kurakata, Akiomi	P01	Lepelletier, Clémence	P13
Kwang, Alexa C.	1A.02, P49	Levesque, Mitch	9A.10
Kwong, Yok Lam	6.04	Lewerin, Catharina	7A.01
L			
La Porta, Agostino	3B.01	Lewis, Julia M.	P49
Lachance, Madeleine	4B.01	Lezcano, Cecilia	1B.07
Lai, Pan	1A.03	Lheure, Coralie	3B.03, 7B.06
Lam, Mun W.	1B.06, P19	Li, Andy	1A.01, 4B.01
Lambert, Christine	P04	Li, Davis	P49
Lampadaki, Kyriaki	3A.01, 3A.06	Li, Mingjia	1A.05, 1A.06
Lange, Sarah J.	7B.05, 9A.04, P35	Liao, Amy	3B.02
Lansigan, Frederick	7B.05, 9A.04, 9B.09, P35	Liao, Viviane	8B.01, 9A.06
		Lim, Megan	4B.09, 8B.01
		Lim, Sean	6.02
		Lin, Stephanie K.	7A.05, 9A.03
		Lindahl, Danijela	6.02
		Linos, Konstantinos	P50

Linsell, Louise	3B.05	Martins, Francisco	4A.02, 9B.07, P03
Litvinov, Ivan V.	9B.06, P04, P12, P39, P41	Marzano, Angelo V.	1B.03
Liu, Fengjie	5.04	Massey, Kenneth D.	6.06
Liu, Vincent	7B.02	Massone, Cesare	3B.01
Liu, Yu	4B.02	Maubec, Eve	P40
Livingstone, Elisabeth	9A.09	Mazzuocolo, Luis D.	P02, P09
Lohray, Rishabh	4A.05, 7B.04, 9B.02	McAllister, Andres	6.02
Loo, Sui-Yen	2.06	McCook-Veal, Ashley	2.02
Loseto, Giacomo	3B.01	McCormack, Christopher J.	3B.05, P31
Louveau, Baptiste	1A.01	Meehan, Shane A.	1A.07
Lu, Kurt Q.	3A.07	Mehta-Shah, Neha	2.02, 3B.02, 6.01, 7B.02, 8A.01, P30, P34
Luongo, Maria B.	P09	Meiß, Frank	7A.04
Lytte, Andrew	1B.07	Melchers, Susanne	9A.09
M			
Ma, Rachel	7A.06, P54	Meledathu, Shannon	1A.07, 3A.03, 8B.02
Machet, Laurent	P40, P45	Melendez, Brenda	4A.04
Madsen, Kristoffer P.	3B.04	Melle, Federica	7B.01
Magalhães, José	9B.07	Meltzer, Rachel	6.07
Maharaj, Lenushka	3B.04	Merken, Tatenda	P28
Mahévas, Thibault	P13	Merkus, Veerle	9A.10
Maillard, Hervé	7B.06	Merli, Michele	1B.03
Maloney, Mackenzie	8B.01	Merlo, Valentina	1B.03
Malpica Castillo	9A.01	Mheidly, Kayane	8A.02
Malpica, Castillo, Luis E.	7B.04	Michel, Catherine	P40
Mancini, Maxence	1A.01	Michel, René P.	P04
Mandel, Jenna L.	P18	Michon, Adrien	P13
Mangold, Aaron	6.06, 1B.01, 7B.02	Millán, Rocío	2.06, P52, P53
Manso, Rebeca	1A.04	Miranda, Roberto N.	4A.04, 7B.04
Manzano, Jomel Meeko	8A.03	Mittal, Bharat	3A.07, P46
Marcheselli, Luigi	3B.01	Mitteldorf, C.	7A.03
Marchi, Enrica	6.04	Miyashiro, Denis	4B.07, P11, P25
Marie-Cardine, Anne	P36	Modi, Dipenkumar	6.06
Marinos, Leonidas	3A.01, 3A.06	Moguelet, Philippe	P13
Marinucci, Laura	7B.01	Mohrbacher, Ann	6.06
Mårtensson, Linda	6.02	Moiin, Ali	6.06
Martín García-Sancho, Alejandro	4B.02	Moins-Teisserenc, Hélène	4B.01, P36, P40, P42
		Molgó, Montserrat	2.06, P52, P53

Montaudié, Henri	P40
Montlahuc, Claire	P40
Moore, Zachary	1B.07, 9A.06
Mootien, Manda D.	8A.04
Moreira, Jonathan	9B.04
Moreno, Chaz	6.01
Moreno-Delgado, María	1A.04
Moreno-Vílchez, Carlos	1A.04
Morgante, Niccolò	3B.04
Morris, Stephen	6.02
Morsia, Erika	3B.01, 8A.02
Mortier, Laurent	P40
Moskovits, Neta	6.05
Moskowitz, Alison	1B.07, 4B.05, 8B.01, 9A.06
Mössinger, Katharina	9A.09
Mou, Eric	2.02, 7B.02
Mourah, Samia	1A.01, P40
Moustaqim-Barrette, Amina	P39
Mouthon, Maxime	1A.01
Moy, Andrea	1B.07, 4A.03, 4B.05, 9A.06
Moyal, Lilach	6.05
Mozdon, Maria	P43
Muniesa, Cristina	1A.04, 7A.03, 8A.02
Murray, Duncan	P19
Musiek, Amy	3B.02, 6.01, 8A.02
Musoro, Jammbe	P38
Myers, Caroline S.	7A.05, 9A.03

N

Nagarajan, Priyadharsini	4A.04
Naidu, Malini P.	1A.07, 3A.03
Nair, Ranjit	7B.04, 9A.01
Najidh, Safa	1A.02
Nardin, Charlée	P45
Nassi, Luca	3B.01, 8A.02
Nayudu, Krithika	6.07, 8A.01, P30, P34

Nebo, Ikenna D.	P48
Nguyen, Anh H.	8B.04
Ni, Xiao	1B.02, P27
Nicolay, Jan P.	6.03, 9A.09, P38, P55
Nieto, Yago	9A.01
Nikbakht, Neda	1B.05, P18, P37
Ninosu, Nadia	P55
Noorani, Mansoor	7B.04
Nukui, Youko	4B.07

O

Ocejo, Stephanie	4A.07
Ogundipe, Iyanuluwa	7B.04
Oh, Christina	9A.06
Olsen, Elise	8A.01, P30, P34
Onida, Francesco	1B.03, 3B.01, 4A.06, 9A.08
Oro, Saskia	3B.03, 7B.06
Ortiz-Romero, Pablo L.	1A.04, 4B.02, 6.03, 9A.08, P38, P42
Ortonne, Nicolas	P36
Osman, Selena	9A.05
Osmancevic, Amra	7A.01
Ostroff, Eleanor B.	3A.04, 3A.07, 4A.07, 4B.06, 9B.04, 9B.08, P46
Otsuka, Atsushi	P05
Ottevanger, Rosanne	8A.01, 8A.02, P30, P33, P34
Owusu-Ansah, Kofi	2.07

P

Pacheco, Teresa	P37
Paiva, Artur	4A.02
Pang, Yanzhen	3A.04, 3A.07
Papadavid, Evangelia	3A.01, 3A.06, 4A.01, 6.03, 9A.08
Papayannidis, Cristina	7A.04
Pappa, Vasiliki	3A.01
Pararajalingam, Prasath	8B.01

Raymundo, Caroline	8A.01, P30	Sacknovitz, Yoni	7A.06, P48, P54
Reardon, Erin	P28	Saiag, Philippe	P40
Rebollo-González, Marcos	1A.04	Said, Rabih	6.01
Reculé, Francisca	P08	Samimi, Sara	9A.03
Ren, Ziyu	3A.04, 3A.07, P46	Sanches, José A.	4B.07, P11, P25
Reneau, John C.	6.04	Sandilands, Kerry	8A.02
Resche-Rigon, Matthieu	P40	Sarnala, Sai	7B.04
Richardson, Jennifer	6.04	Sato, Shinichi	9A.07
Richert, Iseulys	P36	Saulnier, Katia	P36
Rijal, Hibo	P39	Savage, Kerry	1B.07
Rindler, Katharina	1A.07, 8B.02, 9A.08	Scarisbrick, Julia J.	1B.06, 2.01, 2.03, 4A.01, 4B.02, 5.02, 5.03, 5.05, 6.03, 7A.03, 7A.04, 7B.03, 8A.01, 8A.02, 8A.05, 9A.02, 9A.08, P19, P30, P34
Rittig, Anne H.	P44	Scarmoutzos, Louis	6.06
Rocuzzo, Gabriele	3B.01, 5.02, 5.03, 6.03, 7A.04, 7B.03, 8B.04	Schann, Stephan	P36
Rodríguez, Marta	1A.04	Schatz, Jonathan H.	6.01
Rodríguez-Peralto, José Luis	1A.04	Schell, Nicholas	P54
Rodríguez-Pinilla, Socorro María	1A.04	Schepps, Samuel	P18
Roggo, Andrea	9A.10	Schiele, Kristan	9B.09
Rook, Alain H.	7A.05, 9A.03	Schmidt, Moritz	7A.04
Rose, Solène	P36	Schrader, A.M.R.	7A.03, 8B.04, 3A.02
Rosen, Steven T.	2.04, 3A.05, 8A.03	Schrader, Anne-Roos	9A.10
Rosenthal, Allison	6.01, 7B.02	Schultz, Laura C.	3A.05, 8A.03
Rosenwald, Andreas	8B.04	Scribner, Jane	2.02, 7B.02
Rossi, Francesca G.	1B.03	Sebastian, Neenu	1B.06, 8A.05
Rouf, Rejowana	P26	Sebastien, Colin	7B.06
Rozati, Sima	1B.04, 2.02, 4B.08, 7B.02, 8A.02, 9A.08, P10, P37, P54	Sekine, Chikako	P01
Ruan, Jia	6.01	Serret-Larmande, Arnaud	P40
Ruan, Yeping	5.04	Servitje, Octavio	1A.04
Rukundo, Hélène	P41	Sethi, Tarsheen	2.02, 7B.02, P49
Rupoli, Serena	3B.01, 9A.08	Shah, Farida	1B.06, P19
Ryzhikova, Natalya	P23	Shahriari, Neda	6.07
S			
Saba, Nakhle S.	4B.02	Shen, Xiaoyan	5.04
Sabbagh, Laurent	P36	Shi, Ruoshi	6.04

Shimshon, Hadar K.	2.05	Sun, Jingru	1A.05
Shinohara, Michi M.	8A.01, 8A.02, P30, P34, P37, P47	Sundstedt, Anette	6.02
Shohdy, Merna	P47	Sung, Julie K.	P54
Shpall, Elizabeth	9A.01	Sureda, Anna	9A.08
Siddiqui, Nadia	P28	Switchenko, Jeffrey	2.02
Siddiqui, Umar	3A.04	T	
Sidorova, Yulia	P23	Ta, Van Anh	4B.01
Silveira, Luisa P.	2.05	Tabano, Silvia	8B.06, P51
Simeoli, Domenico	1B.03	Takeda, Moe R.	P06
Simula, Maria Pina	3B.01	Tang, Haiming	4B.05
Singh, Amrita Kim	3A.02	Tastanova, Aizhan	9A.10
Sivachandran, Sriraam	9B.06	Tavarozzi, Rita	8B.01
Skamene, Sonia	P04	Tedbirt, Billal	P40
Skov, Lone	3B.04	Tee, Shang-lan	P14
Smith, Marcel	8B.01	Teige, Ingrid	6.02
Sohier, Pierre	P13	Templier, Isabelle	P40
Souza, Bruno C.	4B.07, P11, P25	Tengler, Luisa	9A.09
Spadt, Lauren	9B.03	Teoli, Miriam	3B.01, 8A.02
Specht, Lena	3B.04	Terekhova, Elizaveta	P43
Spigariolo, Cristina B.	7B.01	Theurich, Sebastian	7A.04
Srouf, Samer	7B.04, 9A.01	Thomas, Colin J.	7A.05, 9A.03
Stadler, Rudolf	4B.03, 6.03, 7A.04, 8B.04, 9A.08	Thonnart, Nicolas	P36
Staedler, Davide	8B.03	Thornhill, Hafwen	8A.05
Stagaman, Elise	3A.04	Thornton, Susan	8A.01, 8A.02, P30, P34
Steeghs, E.M.P.	7A.03	Tolu, Seda S.	P54
Stephen, Sasha	6.07	Tomasevic, Nenad	6.04
Stevens, Andrea	P19	Torre-Castro, Juan	1A.04
Straube, Richard	1B.01	Torres, Jennifer L.	9A.01
Streicher, Howard	6.01	Torres-Cabala, Carlos A.	1B.02, 4A.04, 7B.02, 9A.01
Stuver, Robert	1B.07, 4B.05, 4B.09, 8B.01, 9A.06	Tournier, Emilie	P13
Su, Chingyu	3A.05	Trimark, Payton	2.07, 4B.06
Sudarikov, Andrey	P23	Troin, Laura	3B.03, 7B.06, P40, P45
Suemitsu, Yamato	4B.09	Trupiano, Nicole	9B.08
Sugaya, Makoto	9A.07, P01, P16	Tsai, Yi-Chien	8B.03
Suhl, Sara	7A.06, P48, P54	Tucci, Alessandra	3B.01
		Tzoumpa, Sofia	3B.03

U

Uchida, Momoka	P01
Usui, Shunya	P05

V

Valente, Mariana F.	4B.07
Valkema, Pieter A.	3A.02, 8B.04
van der Perk, Kaley R.	3A.02
van der Ploeg, Manon	9A.10
van der Weyden, Carrie	3B.05, P31
Vanderbilt, Chad	4A.03, 4B.09, 8B.01
Vasavda, Chirag	6.07
Vega, Francisco	7B.04
Vega-Mercado, Rene	P49
Venegoni, Luigia	1B.03, 7B.01
Vermeer, Maarten	3A.02, 6.03, 7A.03, 8B.04, 9A.08, 9A.10, P33
Vermot-Desroches, Claudine	P36
Vetsika, Eleni-Kyriaki	3A.01, 3A.06
Viguiet, Manuelle-Anne	P40
Villafuerte, Lillian L.	9B.10
Villarroel, Alejandra	2.06
Villaseca, Miguel Á.	P52, P53
Villasenor-Park, Jennifer	7A.05, 9A.03
Virgen, Cesar A.	1B.07, 4B.07, 8B.01, 9A.06, P20, P47
Vittorio, Carmela C.	7A.05, 9A.03
von Bubnoff, Dagmar	P55
von Bubnoff, Nikolas	P55
Vydianath, Bindu	7A.03, 7A.04

W

Walker, Christina J.	P17
Wallin, Johan E.	6.02
Wan, Fei	6.01
Wang, Alyson	P56
Wang, Yang	1A.03, 1A.05, 1A.06, 5.04

Wang, Yimeng	5.04
Wargo, Jennifer	4A.04
Watkins, Marcus P.	3B.02, 7B.02
Weed, Jason	P54
Weichselbaum, Ralph	3A.07, P46
Whittaker, Sean	9A.08
Wilcox, Ryan	6.06
Willat, Rosario	2.06, P52, P53
Willemze, Rein	2.01, 7A.03, 9A.08
Williams, Madeline N.	P18
Wobser, Marion	7A.03, 8B.04, 9A.09
Wojewoda, Karolina	7A.01
Wolner, Zachary	P28, P37
Wolniak, Kristy	4B.06
Won, Chong Hyun	4B.04, P21
Wu, Alyssa	3A.05, 8A.03
Wu, Susan	7B.04
Wu, Xiwei	3A.05
Wynaendts, Liliane C.	8B.04

X

Xia, Xiaoqing	9A.04
Xiao, Yu	1A.05, 1A.06
Xu, Jie	7B.04, 9A.01
Xu, Ruilin	1A.03
Xue, Ruidong	1A.03

Y

Yachnin, Jeffrey	6.02
Yahalom, Joachim	9A.06
Yamada, Takehiro	P01
Yamamura, Yuto	P05
Yang, Kerry	P22
Yannakou, Costas K.	6.04
Yin, Neo	4A.03
Yoshizaki, Ayumi	9A.07
Yuan, Yate-Ching	3A.05
Yurkevich, Annali	P49

Z

Zachary, Vanderbilt	4B.09
Zain, Jasmine	1B.07, 6.04, 8B.01, 9A.06, 9A.08
Zaminski, Devyn H.	P54
Zamprogno, Marzia	1B.03, 7B.01
Zanga, Haley	9B.09
Zhan, Tingting	P18
Zhang, Bing M.	1A.02
Zhang, Yanming	4B.09

Zhang, Yue	P50
Zhao, Lin Pierre	P13
Zheng, Haoxiang	P49
Zhou, Maggie H.	7A.06, P54
Zhou, Xiaolong	3A.04, 3A.07, 4A.07, 4B.06, 9B.04, 9B.08, P46
Zinzani, Pier Luigi	3B.01, 6.04, 9A.08
Zussino, Martina	P51
Zvonkov, Evgeny	P23

6TH World Congress of
Cutaneous Lymphomas

Montréal







ISCL HEADQUARTERS

675 Tollgate Rd., Suite G, Elgin, IL
60123 USA
Phone: +1-312-585-8941
www.cutaneouslymphoma.org